Antibacterial nitrogen-containing tricyclic compound and use
By developing antibacterial nitrogen-containing tricyclic compounds, the difficulties in treating gonorrhea and urinary tract infections caused by antibiotic resistance have been solved, providing an effective treatment option for bacteria such as Neisseria gonorrhoeae and Escherichia coli.
Patent Information
- Application Number
- PCT/CN2026/094141
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-08-13
- Filing Date
- 2026-04-30
- Publication Date
- 2026-11-12
AI Technical Summary
Due to the overuse of antibiotics, microbial resistance to antibiotics is constantly increasing, leading to a rapid decrease in effective treatments for gonorrhea and urinary tract infections. There is an urgent need to develop new antibiotic compounds that exhibit more effective antimicrobial activity.
A class of antibacterial nitrogen-containing tricyclic compounds is proposed, with the specific structure represented by formula (Ⅰ), containing a combination of various substituents and heteroatom groups, for use in preparing pharmaceutical compositions to treat or prevent infections caused by bacteria such as Neisseria gonorrhoeae and Escherichia coli.
This compound exhibits effective antibacterial activity against bacteria such as Neisseria gonorrhoeae and Escherichia coli, providing new treatment options and reducing the problem of drug resistance.
Smart Images

Figure CN2026094141_12112026_PF_FP_ABST
Abstract
Description
Antibacterial nitrogen-containing tricyclic compounds and their uses
[0001] Priority information
[0002] This application claims priority and benefit to patent application 202510585699.0 filed with the China National Intellectual Property Administration on May 7, 2025 and patent application 202511134852.4 filed with the China National Intellectual Property Administration on August 13, 2025, the entire contents of which are incorporated herein by reference. Technical Field
[0003] This invention relates to the pharmaceutical field, and more specifically, to a class of antibacterial nitrogen-containing tricyclic compounds and their uses. Background Technology
[0004] Since the discovery of penicillin, antibiotics have played a vital role in antimicrobial therapy. However, due to antibiotic overuse, antibiotic resistance in microorganisms is steadily increasing. Antimicrobial resistance is an urgent global health and socioeconomic crisis. It is estimated that 1.27 million people worldwide died from drug-resistant bacterial infections in 2019. Antimicrobial resistance threatens all regions and all age groups, with low- and middle-income countries being the most affected. It has significant impacts on human and animal health, food production, and the environment, and threatens the achievement of several Sustainable Development Goals. The World Bank estimates that, if left unchecked, antimicrobial resistance will cost between $1 trillion and $3.4 trillion annually in GDP by 2030 and increase healthcare costs by $1 trillion by 2050.
[0005] Gonorrhea is a classic sexually transmitted infection caused by Neisseria gonorrhoeae, primarily manifesting as purulent inflammation of the mucous membranes of the genitourinary system. In men, the most common manifestation is urethritis, while in women it is cervicitis. Local complications in men mainly include epididymitis, while in women it is primarily pelvic inflammatory disease. Urinary tract infection (UTI) refers to acute or chronic inflammation caused by the abnormal proliferation of pathogenic microorganisms in the kidneys, ureters, bladder, and urethra. UTIs are very common; approximately 11% of women over 18 years of age experience at least one episode of acute cystitis per year. Of these, half will experience more than one recurrent episode in their lifetime. The peak incidence occurs in young, sexually active women aged 18 to 29.
[0006] For many years, various antibiotics have been used to treat gonorrhea and urinary tract infections (UTIs). However, due to the emergence and global spread of drug resistance, the effective treatment of gonorrhea and UTIs has rapidly decreased. Therefore, there is an urgent need to develop new antibiotic compounds that exhibit more effective antimicrobial activity, particularly for the treatment of gonorrhea and UTIs. Summary of the Invention
[0007] In a first aspect, the present invention provides a compound.
[0008] In one aspect, the present invention provides a compound, which is a compound of formula (I), its tautomer, stereoisomer, or pharmaceutically acceptable salt.
[0009] in,
[0010] W1, W2, W3, and W4 are each independently CR w Or N;
[0011] Each R w The independent components are H, halogen, OH, NH2, CN, CONH2, and C, respectively. 1-6 Alkyl, C 1-6 Alkoxy or C 3-8 cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkoxy and C 3-8 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. ww replace;
[0012] Each R ww They are H, halogen, OH, and C, respectively. 1-6 Alkyl or C 1-6 Alkoxy;
[0013] Each R1 is independently H, oxo (=O), halogen, OH, NH2, CN, COOH, CONH2, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-8 cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkoxy and C 3-8 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. a replace;
[0014] Each R a They are H, halogen, OH, and C, respectively. 1-6 Alkyl or C 1-6 Alkoxy;
[0015] R2 represents H and C. 1-6 Alkyl or C1-6 Halogenated alkyl groups;
[0016] X1, X2, X3, and X4 are each independently N or CR. x1 ;
[0017] Each R x1 They are, independently, H, halogen, OH, NH2, CN, and C. 1-6 Alkyl, C 1-6 Alkylthio, C 1-6 Alkoxy, C 1-6 alkyl carbonyl, C 1-6 alkoxycarbonyl or C 3-8 cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkylthio, C 1-6 Alkoxy, C 1-6 alkyl carbonyl, C 1-6 alkoxycarbonyl and C 3-8 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. b replace;
[0018] Each R b They are H, halogen, OH, NH2, and C, respectively. 1-6 Alkyl or C 1-6 Alkoxy;
[0019] Ring A is C 3-10 Monocyclic cycloalkyl, C 4-10 Bicyclic cycloalkyl, 4-10 member monocyclic heterocyclic alkyl, 5-10 member bicyclic heterocyclic alkyl, 4-10 member monocyclic heterocyclic alkenyl or 5-10 member bicyclic heterocyclic alkenyl;
[0020] Each R3 is independently H, oxo (=O), halogen, OH, NH2, CN, or C. 1-6 Alkyl, C 1-6 Alkoxy or C 3-8 cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkoxy and C 3-8 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. c replace;
[0021] Each R c They are H, halogen, OH, NH2, and C, respectively. 1-6 Alkyl or C 1-6 Alkoxy;
[0022] m can be 1, 2, 3, or 4;
[0023] n is 1, 2, 3 or 4;
[0024] The heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" contains N, O or S, and the number of the heteroatom groups is 1, 2, 3 or 4; when the number of the heteroatom groups is multiple, the heteroatom groups may be the same or different;
[0025] The conditions are:
[0026] When W1 and W4 are CR w When ring A is C 4-10 Bicyclic cycloalkyl, 5-10 membered bicyclic heterocyclic alkyl or 5-10 membered bicyclic heterocyclic alkenyl.
[0027] On the other hand, the present invention proposes a compound, which is the compound of formula (I), its tautomer, stereoisomer, or pharmaceutically acceptable salt.
[0028] in,
[0029] W1, W2, W3, and W4 are each independently CR w Or N;
[0030] Each R w The independent components are H, halogen, OH, NH2, CN, CONH2, and C, respectively. 1-6 Alkyl, C 1-6 Alkoxy or C 3-8 cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkoxy and C 3-8 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. ww replace;
[0031] Each R ww They are H, halogen, OH, and C, respectively. 1-6 Alkyl or C 1-6 Alkoxy;
[0032] Each R1 is independently H, oxo (=O), halogen, OH, NH2, CN, COOH, CONH2, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-8 cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkoxy and C 3-8 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. a replace;
[0033] Each R a They are H, halogen, OH, and C, respectively. 1-6 Alkyl or C 1-6 Alkoxy;
[0034] R2 represents H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups;
[0035] X1, X2, X3, and X4 are each independently N or CR. x1 ;
[0036] Each R x1 They are, independently, H, halogen, OH, NH2, CN, and C. 1-6 Alkyl, C 1-6 Alkylthio, C 1-6 Alkoxy, C 1-6 alkyl carbonyl, C 1-6 alkoxycarbonyl or C 3-8 cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkylthio, C 1-6 Alkoxy, C 1-6 alkyl carbonyl, C 1-6 alkoxycarbonyl and C 3-8 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. b replace;
[0037] Each R b They are H, halogen, OH, NH2, and C, respectively. 1-6 Alkyl or C 1-6 Alkoxy;
[0038] Ring A is C 3-10 Monocyclic cycloalkyl, C 4-10 Bicyclic cycloalkyl, 4-10 member monocyclic heterocyclic alkyl, 5-10 member bicyclic heterocyclic alkyl, 4-10 member monocyclic heterocyclic alkenyl or 5-10 member bicyclic heterocyclic alkenyl;
[0039] Each R3 is independently H, halogen, OH, NH2, CN, or C. 1-6 Alkyl, C 1-6 Alkoxy or C 3-8 cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkoxy and C 3-8 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. c replace;
[0040] Each R c They are H, halogen, OH, NH2, and C, respectively. 1-6 Alkyl or C 1-6 Alkoxy;
[0041] m can be 1, 2, 3, or 4;
[0042] n is 1, 2, 3 or 4;
[0043] The heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" contains N, O or S, and the number of the heteroatom groups is 1, 2, 3 or 4; when the number of the heteroatom groups is multiple, the heteroatom groups may be the same or different;
[0044] The conditions are:
[0045] When W1 and W4 are CR w When ring A is C 4-10 Bicyclic cycloalkyl, 5-10 membered bicyclic heterocyclic alkyl or 5-10 membered bicyclic heterocyclic alkenyl.
[0046] According to embodiments of the present invention, the above-described compound may further include at least one of the following technical features:
[0047] In an optional embodiment of the present invention, each R w The independent components are H, halogen, OH, NH2, CN, CONH2, and C, respectively. 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 cycloalkyl, the C 1-4 Alkyl, C 1-4 Alkoxy and C 3-6 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. ww replace.
[0048] In an optional embodiment of the present invention, each R w Each is independently represented by H.
[0049] In an optional embodiment of the present invention, W1, W2, W3 and W4 are each independently CH or N.
[0050] In an optional embodiment of the present invention, W1, W2 and W3 are each independently CH, and W4 is N.
[0051] In an optional embodiment of the present invention, W1, W2 and W4 are each independently CH, and W3 is N.
[0052] In one optional embodiment of the present invention for
[0053] In one optional embodiment of the present invention for
[0054] In one optional embodiment of the present invention for
[0055] In an optional embodiment of the present invention, each R1 is independently H, halogen, OH, NH2, CN, COOH, CONH2, C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 cycloalkyl, the C 1-4 Alkyl, C 1-4 Alkoxy and C 3-6 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. a replace.
[0056] In an optional embodiment of the present invention, each R1 is independently H.
[0057] In an optional embodiment of the present invention, m is 1, 2, 3 or 4.
[0058] In an optional embodiment of the present invention, R2 is H or C. 1-3 Alkyl or C 1-3 Halogenated alkyl groups.
[0059] In an optional embodiment of the present invention, R2 is H.
[0060] In an optional embodiment of the present invention, each R x1 They are, independently, H, halogen, OH, NH2, CN, and C. 1-4 Alkyl, C 1-4 Alkylthio, C 1-4 Alkoxy, C 1-4 alkyl carbonyl, C 1-4 alkoxycarbonyl or C 3-6 cycloalkyl, the C 1-4 Alkyl, C 1-4 Alkylthio, C 1-4 Alkoxy, C 1-4 alkyl carbonyl, C 1-4 alkoxycarbonyl and C 3-6 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. b replace.
[0061] In an optional embodiment of the present invention, each R x1 Each is independently represented by H.
[0062] In one optional embodiment of the present invention for
[0063] In an optional embodiment of the present invention, X1, X2, X3 and X4 are each independently N or CH.
[0064] In an optional embodiment of the present invention, X1, X2 and X4 are each independently CH, and X3 is N.
[0065] In an optional embodiment of the present invention, X2, X3 and X4 are each independently CH, and X1 is N.
[0066] In one optional embodiment of the present invention for
[0067] In one optional embodiment of the present invention for
[0068] In one optional embodiment of the present invention for
[0069] In one optional embodiment of the present invention for
[0070] In an optional embodiment of the present invention, ring A is a 5-6 member monocyclic heterocyclic alkyl group, a 6-8 member bicyclic heterocyclic alkyl group, a 5-6 member monocyclic heterocyclic alkenyl group, or a 6-8 member bicyclic heterocyclic alkenyl group.
[0071] In an optional embodiment of the present invention, ring A is a 6-8 membered bicyclic heterocyclic alkyl group or a 6-8 membered bicyclic heterocyclic alkenyl group, wherein the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl group or the 6-8 membered bicyclic heterocyclic alkenyl group are each independently a spirocyclic ring, a bridged ring, or a fused ring.
[0072] In one optional embodiment of the present invention for When ring A is a 5-6 member monocyclic heterocyclic alkyl, a 6-8 member bicyclic heterocyclic alkyl, a 5-6 member monocyclic heterocyclic alkenyl, or a 6-8 member bicyclic heterocyclic alkenyl.
[0073] In one optional embodiment of the present invention for When ring A is a 5-6 member monocyclic heterocyclic alkyl, a 6-8 member bicyclic heterocyclic alkyl, a 5-6 member monocyclic heterocyclic alkenyl, or a 6-8 member bicyclic heterocyclic alkenyl, the bicyclic rings in the 6-8 member bicyclic heterocyclic alkyl or 6-8 member bicyclic heterocyclic alkenyl are each independently a spirocyclic, bridged, or fused ring, and the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" is O.
[0074] In one optional embodiment of the present invention for Ring A is a 6-8 membered bicyclic heterocyclic alkyl or a 6-8 membered bicyclic heterocyclic alkenyl group, wherein the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl or 6-8 membered bicyclic heterocyclic alkenyl group are each independently a spirocyclic ring, a bridged ring, or a fused ring, and the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" group is O.
[0075] In one optional embodiment of the present invention for Ring A is a 5-6 membered monocyclic heterocyclic alkyl or a 5-6 membered monocyclic heterocyclic alkenyl, wherein the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" is O.
[0076] In one optional embodiment of the present invention for In this case, ring A is a 6-8 membered bicyclic heterocyclic alkyl group or a 6-8 membered bicyclic heterocyclic alkenyl group.
[0077] In one optional embodiment of the present invention for In this case, ring A is a 6-8 membered bicyclic heterocyclic alkyl or a 6-8 membered bicyclic heterocyclic alkenyl, wherein each bicyclic ring in the 6-8 membered bicyclic heterocyclic alkyl or 6-8 membered bicyclic heterocyclic alkenyl is independently a spirocyclic ring, and the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" is N.
[0078] In one optional embodiment of the present invention for
[0079] In one optional embodiment of the present invention for
[0080] R4 represents H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups.
[0081] In one optional embodiment of the present invention for
[0082] R4 represents H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups.
[0083] In an optional embodiment of the present invention, each R3 is independently H, oxo (=O), halogen, OH, NH2, CN, or C. 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 cycloalkyl, the C 1-4 Alkyl, C 1-4 Alkoxy and C 3-6 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. c replace.
[0084] In an optional embodiment of the present invention, each R3 is independently H, halogen, OH, NH2, CN, or C. 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 cycloalkyl, the C 1-4 Alkyl, C 1-4 Alkoxy and C 3-6 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. c replace.
[0085] In an optional embodiment of the present invention, each R3 is independently H or oxidized (=O).
[0086] In an optional embodiment of the present invention, each R3 is independently H.
[0087] In an optional embodiment of the present invention, each R4 is independently H.
[0088] In an optional embodiment of the present invention, n is 1, 2, 3, or 4. In an optional embodiment of the present invention, Each R3 is independently H.
[0089] In one optional embodiment of the present invention for R3 is an oxometalate (=O). In an optional embodiment of the invention, for Each R3 is independently H.
[0090] In one optional embodiment of the present invention for R3 stands for oxygen (=O).
[0091] In one optional embodiment of the present invention for
[0092] In one optional embodiment of the present invention for
[0093] In one optional embodiment of the present invention for
[0094] In one optional embodiment of the present invention for
[0095] In an optional embodiment of the present invention, the compound of the present invention has the structural formula (I-1):
[0096] in,
[0097] Ring A is C 4-10 Bicyclic cycloalkyl, 5-10 membered bicyclic heterocyclic alkyl or 5-10 membered bicyclic heterocyclic alkenyl;
[0098] R w R1, R2, R3, X1, X2, X3, X4, m, and n are as defined in this invention.
[0099] In an optional embodiment of the present invention, the compound of the present invention has the structural formula (Ⅰ-1A):
[0100] in,
[0101] Ring A is C 4-10 Bicyclic cycloalkyl, 5-10 membered bicyclic heterocyclic alkyl or 5-10 membered bicyclic heterocyclic alkenyl;
[0102] R w R1, R2, R3, X1, X2, X3, X4, m, and n are as defined in this invention.
[0103] In an optional embodiment of the present invention, in structural formula (Ⅰ-1) or structural formula (Ⅰ-1A), ring A is a 6-8 membered bicyclic heterocyclic alkyl group or a 6-8 membered bicyclic heterocyclic alkenyl group.
[0104] In an optional embodiment of the present invention, in structural formula (Ⅰ-1) or structural formula (Ⅰ-1A), ring A is a 6-8 membered bicyclic heterocyclic alkyl group or a 6-8 membered bicyclic heterocyclic alkenyl group, wherein the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl group or the 6-8 membered bicyclic heterocyclic alkenyl group are each independently a spirocyclic ring, a bridged ring, or a fused ring.
[0105] In an optional embodiment of the present invention, in structural formula (Ⅰ-1) or structural formula (Ⅰ-1A), for
[0106] In an optional embodiment of the present invention, in structural formula (Ⅰ-1) or structural formula (Ⅰ-1A), for
[0107] In an optional embodiment of the present invention, in structural formula (Ⅰ-1) or structural formula (Ⅰ-1A), for Ring A is a 6-8 membered bicyclic heterocyclic alkyl or a 6-8 membered bicyclic heterocyclic alkenyl group, wherein the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl or 6-8 membered bicyclic heterocyclic alkenyl group are each independently a spirocyclic ring, a bridged ring, or a fused ring, and the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" group is O.
[0108] In an optional embodiment of the present invention, in structural formula (Ⅰ-1) or structural formula (Ⅰ-1A), for Ring A is a 6-8 membered bicyclic heterocyclic alkyl or a 6-8 membered bicyclic heterocyclic alkenyl group, wherein each of the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl or 6-8 membered bicyclic heterocyclic alkenyl group is independently a spirocyclic ring, and the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" group is N. In an optional embodiment of the present invention, in structural formula (I-1) or structural formula (I-1A), for
[0109] In an optional embodiment of the present invention, in structural formula (Ⅰ-1) or structural formula (Ⅰ-1A), for
[0110] In an optional embodiment of the present invention, in structural formula (Ⅰ-1) or structural formula (Ⅰ-1A), for
[0111] In an optional embodiment of the present invention, in structural formula (Ⅰ-1) or structural formula (Ⅰ-1A), for
[0112] In an optional embodiment of the present invention, the compound of the present invention has the structural formula (I-2):
[0113] in,
[0114] Ring A is a 5-10 membered bicyclic heterocyclic alkyl group or a 5-10 membered bicyclic heterocyclic alkenyl group;
[0115] R w R1, R2, R3, m, and n are as defined in this invention.
[0116] In an optional embodiment of the present invention, the compound of the present invention has the structural formula (Ⅰ-2A):
[0117] in,
[0118] Ring A is a 5-10 membered bicyclic heterocyclic alkyl group or a 5-10 membered bicyclic heterocyclic alkenyl group;
[0119] Rw R1, R2, R3, m, and n are as defined in this invention.
[0120] In an optional embodiment of the present invention, in structural formula (I-2) or structural formula (I-2A), ring A is a 6-8 membered bicyclic heterocyclic alkyl group or a 6-8 membered bicyclic heterocyclic alkenyl group, wherein the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl group or the 6-8 membered bicyclic heterocyclic alkenyl group are each independently a spirocyclic ring, a bridged ring, or a fused ring.
[0121] In an optional embodiment of the present invention, in structural formula (I-2) or structural formula (I-2A), ring A is a 6-8 membered bicyclic heterocyclic alkyl or a 6-8 membered bicyclic heterocyclic alkenyl, wherein the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl or the 6-8 membered bicyclic heterocyclic alkenyl are each independently a spirocyclic ring, a bridged ring, or a fused ring, and the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" is O.
[0122] In an optional embodiment of the present invention, in structural formula (I-2) or structural formula (I-2A), ring A is a 6-8 membered bicyclic heterocyclic alkyl or a 6-8 membered bicyclic heterocyclic alkenyl, wherein each of the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl or the 6-8 membered bicyclic heterocyclic alkenyl is independently a spirocyclic or a bridged ring, and the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" is O.
[0123] In an optional embodiment of the present invention, in structural formula (Ⅰ-2) or structural formula (Ⅰ-2A), for
[0124] In an optional embodiment of the present invention, in structural formula (Ⅰ-2) or structural formula (Ⅰ-2A), for
[0125] In an optional embodiment of the present invention, the above-mentioned compound is selected from any of the following compounds or their tautomers, stereoisomers or pharmaceutically acceptable salts:
[0126] In an optional embodiment of the present invention, the above-mentioned compound is selected from any of the following compounds or their tautomers, stereoisomers or pharmaceutically acceptable salts:
[0127] In a second aspect, the present invention provides a pharmaceutical composition comprising the above-described compound or its tautomers, stereoisomers or pharmaceutically acceptable salts thereof.
[0128] In an optional embodiment of the present invention, the above-described pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient.
[0129] In a third aspect, the present invention provides for the use of the compounds described in the first aspect above, or their tautomers, stereoisomers, or pharmaceutically acceptable salts, or the pharmaceutical compositions described in the second aspect of the present invention, in the preparation of medicaments for the treatment or prevention of infections and diseases caused by bacteria in mammals.
[0130] In an optional embodiment of the invention, the infection includes an infection caused by Neisseria gonorrhoeae or a simple urinary tract infection.
[0131] In an optional embodiment of the invention, the infection includes an infection caused by Escherichia coli or Staphylococcus aureus.
[0132] In a fourth aspect, the present invention provides for the use of the compounds described in the first aspect above, or their tautomers, stereoisomers, or pharmaceutically acceptable salts, or the pharmaceutical compositions described in the second aspect of the present invention, in the treatment or prevention of infections and diseases caused by bacteria in mammals.
[0133] In an optional embodiment of the invention, the infection includes an infection caused by Neisseria gonorrhoeae or a simple urinary tract infection.
[0134] In an optional embodiment of the invention, the infection includes an infection caused by Escherichia coli or Staphylococcus aureus.
[0135] In a fifth aspect, the present invention provides the compounds described in the first aspect above, or their tautomers, stereoisomers, or pharmaceutically acceptable salts, or the pharmaceutical compositions described in the second aspect of the present invention, for the treatment or prevention of infections and diseases caused by bacteria in mammals.
[0136] In an optional embodiment of the invention, the infection includes an infection caused by Neisseria gonorrhoeae or a simple urinary tract infection.
[0137] In an optional embodiment of the invention, the infection includes an infection caused by Escherichia coli or Staphylococcus aureus.
[0138] In a sixth aspect, the present invention provides a method for treating or preventing infections and diseases caused by bacteria in mammals, comprising: administering to a subject a pharmaceutically acceptable dose of a compound described in the first aspect above, or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition described in the second aspect of the present invention.
[0139] In an optional embodiment of the invention, the infection includes an infection caused by Neisseria gonorrhoeae or a simple urinary tract infection.
[0140] In an optional embodiment of the invention, the infection includes an infection caused by Escherichia coli or Staphylococcus aureus.
[0141] Terms and Definitions
[0142] Unless otherwise stated, the terms and definitions used in this application, including those set forth in the specification and claims, are as follows.
[0143] Those skilled in the art will understand that, according to the conventions used in the art, in the structural formula of this application, Used to describe chemical bonds, which are points where a portion or a substituent is connected to a core or skeletal structure. As used herein, “R1”, “R1”, and “R” are used to describe chemical bonds. 1 The meanings of "" are the same and they can be used interchangeably. The same definition applies to other symbols such as R2.
[0144] Unless otherwise specified, the term "pharmaceutical acceptable" refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of reliable medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.
[0145] Unless otherwise specified, the term "pharmaceutically acceptable salt" means a pharmaceutically acceptable non-toxic salt of an acid or base, including salts of inorganic acids and bases, and salts of organic acids and bases.
[0146] In addition to pharmaceutically acceptable salts, the present invention also contemplates other salts. These may serve as intermediates in the purification of compounds or in the preparation of other pharmaceutically acceptable salts, or may be used for the identification, characterization, or purification of the compounds of the present invention.
[0147] Unless otherwise specified, the term "pharmaceutical composition" means a mixture of one or more compounds described in this text or their physiologically / pharmaceutical acceptable salts or prodrugs with other chemical components, such as physiologically / pharmaceutical acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate the administration of the compound to a living organism.
[0148] Unless otherwise specified, the term "excipient" refers to a pharmaceutically acceptable inert ingredient. Examples of the term "excipient" include, without limitation, binders, disintegrants, lubricants, flow aids, stabilizers, fillers, and diluents. Excipients enhance the handling properties of pharmaceutical formulations, i.e., by increasing flowability and / or adhesion, making the formulation more suitable for direct compression.
[0149] Unless otherwise specified, the term "stereoisomer" refers to isomers that are produced by different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, non-corresponding isomers, and conformational isomers.
[0150] Depending on the choice of raw materials and methods, the compounds of the present invention may exist as one or a mixture of possible isomers, for example as purely optical isomers, or as mixtures of isomers, such as racemic and diastereomeric mixtures, depending on the number of asymmetric carbon atoms. When describing optically active compounds, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule with respect to the chiral center (or multiple chiral centers) in the molecule. The prefixes D and L or (+) and (–) are symbols used to specify the plane-polarized rotation of light induced by the compound, where (–) or L indicates that the compound is levorotatory. Compounds with the prefix (+) or D are dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. Specific stereoisomers may also be called enantiomers, and mixtures of said isomers are generally referred to as mixtures of enantiomers. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which can occur when there is no stereoselectivity or stereospecificity in a chemical reaction or method. Many geometric isomers of alkenes, C=N double bonds, etc., can also exist in the compounds described herein, and all such stable isomers are considered in this invention. When the compounds described herein contain an alkene double bond, unless otherwise stated, such double bond includes E and Z geometric isomers. If the compound contains a disubstituted cycloalkyl group, the substituent of the cycloalkyl group may be in cis or trans (cis- or trans-) configuration.
[0151] When the bonds of the chiral carbon in the formulas of this invention are depicted as straight lines, it should be understood that both the (R) and (S) configurations of the chiral carbon and the resulting enantiomerically pure compounds and mixtures thereof are included within the scope of the general formula. The illustration of racemic or enantiomerically pure compounds in this document is derived from Maehr, J. Chem. Ed. 1985, 62:114-120. Unless otherwise stated, wedge-shaped and dashed bonds represent the absolute configuration of a stereocenter.
[0152] Optically active (R)- or (S)-isomers can be prepared using chiral synthons or chiral formulations, or resolved using conventional techniques. Compounds of the present invention containing asymmetrically substituted carbon atoms can be separated in either an optically active or racemic form. Resolution of racemic mixtures of compounds can be performed by any of many methods known in the art. Exemplary methods include fractional recrystallization using a chiral resolving acid, which is an optically active salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids such as tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, or various optically active camphorsulfonic acids such as the D and L forms of β-camphorsulfonic acid. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure α-methylbenzylamine (e.g., S and R forms or diastereoisomeric forms), 2-phenylglycine, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, etc. Resolution of racemic mixtures can also be achieved by elution onto a chromatographic column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). High-performance liquid chromatography (HPLC) or supercritical fluid chromatography (SFC) can be used. The specific method, elution conditions, and column selection can be chosen by those skilled in the art based on the structure of the compound and experimental results. Furthermore, any enantiomer or diastereomeric form of the compound described in this invention can be obtained through stereoorganic synthesis using optically pure starting materials or reagents with known configurations.
[0153] Unless otherwise specified, the term "tautomer" refers to a functional group isomer resulting from the rapid movement of an atom between two positions in a molecule. The compounds of this invention can exhibit tautomerism. Tautomeric compounds can exist in two or more interconvertible forms. Proton-transfer tautomers arise from the migration of covalently bonded hydrogen atoms between two atoms. Tautomers generally exist in equilibrium form, and attempts to isolate a single tautomer usually produce a mixture whose physicochemical properties are consistent with those of the mixture of compounds. The equilibrium position depends on the intramolecular chemical characteristics. For example, in many aliphatic aldehydes and ketones such as acetaldehyde, the ketone form is dominant; while in phenols, the enol form is dominant. This invention encompasses all tautomeric forms of the compounds.
[0154] In examples of the present invention, the proton can occupy two or more positions in the cyclic form of the heterocyclic system, for example, 1H- and 3H-imidazolium, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole, tetrazolium, and 1H- and 2H-pyrazole. The tautomer form can be in equilibrium or spatially fixed in one form through appropriate substitution. For example:
[0155] Unless otherwise specified, use wedge-shaped solid line keys. and wedge-shaped dashed key The absolute configuration of the center of a solid is represented by a straight solid line key. and straight dashed key Represents the relative configuration of the center of a solid.
[0156] The compounds of this invention may contain atomic isotopes in non-natural proportions on one or more atoms constituting the compound. For example, the compounds may be labeled with radioactive isotopes, such as deuterium. 2 H), tritium ( 3 H), Iodine-125 125 I) or C-14 14 C). All isotopic variations of the compounds of the present invention, regardless of radioactivity, are included within the scope of the present invention.
[0157] For pharmaceuticals or pharmacologically active agents, the term "effective amount" or "therapeutic effective amount" refers to a sufficient quantity of a drug or agent that is non-toxic but achieves the desired effect. For the oral dosage forms of this invention, the "effective amount" of one active substance in the composition refers to the amount required to achieve the desired effect when used in combination with another active substance in the composition. The determination of the effective amount varies from person to person, depending on the recipient's age and general condition, as well as the specific active substance. A suitable effective amount in any given case can be determined by a person skilled in the art through routine testing.
[0158] Unless otherwise specified, the terms “active ingredient,” “therapeutic agent,” “active substance,” or “active agent” refer to a chemical entity that can effectively treat a target disorder, disease, or condition.
[0159] Unless otherwise specified, the term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, including deuterium and hydrogen variants, provided that the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is a ketone group (i.e., =O), it means that two hydrogen atoms are replaced. Ketone substitution does not occur on aromatic groups.
[0160] Unless otherwise specified, the terms “optional” or “optionally” refer to events or conditions described below that may but are not required to occur, and the description includes both cases where said events or conditions occur and cases where said events or conditions do not occur.
[0161] Unless otherwise specified, the terms “optionally substituted,” “optionally substituted with…” or “optionally substituted with…” mean that something may or may not be substituted, and unless otherwise specified, the type and number of substituents may be arbitrary on the basis that is chemically feasible.
[0162] When any variable (e.g., R) appears more than once in the composition or structure of a compound, its definition is independent in each case. Therefore, for example, if a group is substituted by 0-2 Rs, the group can optionally be substituted by at most two Rs, and R has independent options in each case. Furthermore, combinations of substituents and / or their variants are only permitted if such combinations produce stable compounds. Additionally, when polycyclic (fused, spirocyclic, or bridged) rings are substituted, it means that the hydrogen atoms on each ring can potentially be substituted.
[0163] In this application, the term "alkyl" refers to a saturated straight-chain or branched monovalent hydrocarbon group containing 1 to 20 carbon atoms, either alone or as part of other substituents, wherein the alkyl group may optionally be substituted by one or more substituents described in this invention. In some embodiments, the alkyl group contains 1-20 carbon atoms (C... 1-20 In some embodiments, the alkyl group comprises 1 to 12 carbon atoms (C1 to C2). 1-12 In some embodiments, the alkyl group comprises 1 to 10 carbon atoms (C). 1-10 In some embodiments, the alkyl group comprises 1 to 6 carbon atoms (C6H ...7H6H6H6H6H6H6 1-6 In some embodiments, the alkyl group contains 1 to 3 carbon atoms (C). 1-3 Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl, 1,2-dimethylbutyl, etc.
[0164] In this application, the term "C" is used either alone or as part of other substituents. α-β "Alkyl" refers to an alkyl group containing a minimum of α and a maximum of β carbon atoms in a branched, linear, or any combination of these three relationships, where α and β represent integers. It can also be represented by "C". α -C β The form "alkyl" is used. C0 alkyl indicates a straight bond.
[0165] In this application, the term "alkenyl" refers to a straight-chain or branched monovalent hydrocarbon group containing 2-12 carbon atoms, wherein there is at least one unsaturated site, i.e., one carbon-carbon sp. 2The double bond, wherein the alkenyl group may optionally be substituted by one or more substituents described in this invention, including the orientation of "cis" and "tans", or the orientation of "E" and "Z". In some embodiments, the alkenyl group comprises 2-12 carbon atoms (C... 2-12 In some embodiments, the alkenyl group comprises 2-8 carbon atoms (C). 2-8 In some embodiments, the alkenyl group comprises 2-6 carbon atoms (C6H ...7H6H6H6H6H6H6H7H6H6H6H6H6H7 2-6 In some embodiments, the alkenyl group comprises 2-4 carbon atoms (C). 2-4 Examples of alkenyl groups include, but are not limited to, vinyl (-CH=CH2), allyl (-CH2CH=CH2), and so on.
[0166] In this application, the term "alkoxy" refers to an alkyl group attached to the remainder of the molecule by an oxygen atom, either alone or as part of other substituents, or is represented as alkyl-O-alkyl, where the oxygen atom may be attached to either a carbon atom of the straight chain of the alkyl group or any carbon atom of the straight chain, wherein the alkyl group has the meaning as described herein. In some embodiments, the alkoxy group contains 1-12 carbon atoms (C... 1-12 In some implementations, the alkoxy group contains 1-6 carbon atoms (C). 1-6 In some implementations, the alkoxy group contains 1-4 carbon atoms (C). 1-4 In some implementations, the alkoxy group contains 1-3 carbon atoms (C). 1-3 The alkoxy group may optionally be replaced by one or more substituents described in this invention. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, 2-methyl-2-propoxy, 1-pentoxy, 2-pentoxy, 3-pentoxy, 2-methyl-2-butoxy, 3-methyl-2-butoxy, 3-methyl-1-butoxy, 2-methyl-1-butoxy, CH3-O-CH2-, etc.
[0167] In this application, the term "alkylthio" means, alone or as part of other substituents, an alkyl group attached to the remainder of the molecule by a sulfur atom (-S-), wherein the alkyl group has the meaning as described in this invention.
[0168] In this application, the term "alkyl carbonyl" means, either alone or as part of other substituents, that an alkyl group is attached to the remainder of the molecule by a carbonyl group (-CO-), wherein the alkyl group has the meaning as described in this invention.
[0169] In this application, the term "alkoxycarbonyl" means, either alone or as part of other substituents, that an alkoxy group is attached to the remainder of the molecule via a carbonyl group (-C(=O)-), wherein the alkoxy group has the meaning as described in this invention.
[0170] In this application, the terms “haloalkyl,” “haloalkenyl,” or “haloalkoxy” mean alkyl, alkenyl, or alkoxy groups substituted with one or more halogen atoms, whether alone or as part of other substituents. Examples of such substituents include, but are not limited to, trifluoromethyl, trifluoromethoxy, etc.
[0171] In this application, the term "cycloalkyl" refers to a monovalent or polyvalent saturated monocyclic, bicyclic, or tricyclic system containing 3-12 carbon atoms, either alone or as part of other substituents, wherein bicyclic or tricyclic systems include spirocyclic, fused, and bridged rings. In some embodiments, the cycloalkyl group comprises 3-12 carbon atoms (C... 3-12 In some embodiments, the cycloalkyl group contains 3-8 carbon atoms (C60-C82). 3-8 In some embodiments, the cycloalkyl group contains 3-6 carbon atoms (C64-C64). 3-6 The cycloalkyl group may be independently unsubstituted or substituted by one or more substituents described in this invention. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, [2.2.2]bicyclooctane, etc.
[0172] In this application, the term "aryl" refers to a monocyclic, bicyclic, or tricyclic carbocyclic system containing 6-14 ring atoms, 6-12 ring atoms, or 6-10 ring atoms, wherein at least one ring system is aromatic, and each ring system comprises a ring of 3-7 atoms and has one or more bonding sites attached to the remainder of the molecule. In some embodiments, the aryl group comprises 6-14 carbon atoms (C... 6-14 In some embodiments, the aryl group comprises 6-12 carbon atoms (C6H ...7H6H6H6H6H6H 6-12 In some embodiments, the aryl group comprises 6-10 carbon atoms (C6H ...7H6H6H6H6H6H 6-10 The aryl group may be independently unsubstituted or substituted by one or more substituents described in this invention. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracene, etc.
[0173] In this application, Cn-n+m or Cn-Cn+m includes any specific case of n to n+m carbons, either alone or as part of other substituents, for example, C 1-12 Including C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 C11 and C 12 It also includes any range from n to n+m, such as C 1-12 Including C 1-3 C 1-6 C 1-9 C 3-6 C 3-9 C 3-12 C 6-9 C 6-12 and C 9-12 Similarly, n-membered to n+m-membered rings represent the number of atoms in the ring from n to n+m. For example, 3-12-membered rings include 3-membered, 4-membered, 5-membered, 6-membered, 7-membered, 8-membered, 9-membered, 10-membered, 11-membered, and 12-membered rings, and also any range from n to n+m. For example, 3-12-membered rings include 3-6-membered, 3-9-membered, 5-6-membered, 5-7-membered, 6-7-membered, 6-8-membered, and 6-10-membered rings, etc.
[0174] In this application, the terms "heteroaryl," "heteroaryl ring," or "heteroarylcycloyl" are used interchangeably, either alone or as part of other substituents, to refer to a monocyclic, bicyclic, or polycyclic cyclic system containing 5-12 ring atoms, at least one ring system being aromatic, preferably 5-10 ring atoms, 5-8 ring atoms, more preferably 5-6 ring atoms, wherein one, two, three, or more ring atoms are heteroatoms and the remaining atoms are carbon, the heteroatoms being independently selected from O, N, or S, and the number of heteroatoms is preferably one, two, or three. The "heteroaryl," "heteroaryl ring," or "heteroarylcycloyl" term may optionally be replaced by one or more substituents described in this invention. Examples of "heteroaryl", "heteroary ring", and "heteroary cyclic group" include, but are not limited to, 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrroleyl, 2-pyrroleyl, 3-pyrroleyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2 -pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (e.g., 2-pyrazolyl), isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2 3-Triazolyl, 1,2,3-Thiodiazolyl, 1,3,4-Thiodiazolyl, 1,2,5-Thiodiazolyl, pyrazinyl, 1,3,5-triazinyl; also including, but not limited to, the following bicyclic compounds: benzimidazolyl, benzofuranyl, benzothiopheneyl, indoleyl (e.g., 2-indoleyl), purinyl, quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), isoquinolinyl (e.g., 1- Isoquinolinyl, 3-isoquinolinyl or 4-isoquinolinyl), imidazo[1,2-a]pyridyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridyl, etc.
[0175] In this application, the term "heterocyclic group," whether alone or as part of other substituents, refers to a saturated or partially unsaturated monocyclic, bicyclic, or polycyclic hydrocarbon substituent, having a non-aromatic structure, comprising 3-20 ring atoms, wherein one, two, three, or more ring atoms are selected from N, O, or S, and the remaining ring atoms are C. The heterocyclic group may optionally be substituted by one or more substituents described in this invention. Preferably, it comprises 3-12 ring atoms (3-12-membered heterocyclic group), more preferably 3-10 ring atoms (3-10-membered heterocyclic group), or 3-8 ring atoms (3-8-membered heterocyclic group), or 3-6 ring atoms (3-6-membered heterocyclic group), or 4-6 ring atoms (4-6-membered heterocyclic group), or 5-6 ring atoms (5-6-membered heterocyclic group). The number of heteroatoms is preferably 1-4, more preferably 1-3 (i.e., 1, 2, or 3). Examples of monocyclic heterocyclic groups include, but are not limited to, pyrrolidinyl, imidazoalkyl, tetrahydrofuranyl, dihydropyrrolidinyl, piperidinyl, piperazinyl, pyranyl, etc. Bicyclic or polycyclic heterocyclic groups include spirocyclic, fused-ring, and bridged-ring heterocyclic groups.
[0176] In this application, the term "heterocyclic alkyl" refers to a saturated "heterocyclic group" as defined above, comprising 3-20 ring atoms, wherein one, two, three, or more ring atoms are selected from N, O, or S, and the remaining ring atoms are C. The heterocyclic alkyl group may optionally be substituted by one or more substituents described in this invention. Preferably, it comprises 3-12 ring atoms (3-12-membered heterocyclic alkyl), more preferably 3-8 ring atoms (3-8-membered heterocyclic alkyl), or 5-10 ring atoms (5-10-membered heterocyclic alkyl), or 5-7 ring atoms (5-7-membered heterocyclic alkyl), or 4-6 ring atoms (4-6-membered heterocyclic alkyl), or 5-6 ring atoms (5-6-membered heterocyclic alkyl). The number of heteroatoms is preferably 1-4, more preferably 1-3 (i.e., 1, 2, or 3). Examples of heterocyclic alkyl groups include, but are not limited to, oxetyl, aziridine, oxetyl, thioheterobutyl, pyrrolidinyl, pyrazolyl, imidazoalkyl, tetrahydrothiopheneyl (including tetrahydrothiophene-2-yl and tetrahydrothiophene-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxyl, dithiaalkyl, isoxazolyl, isothiazolyl, 1,2-oxazinyl, 1,2-thiaazinyl, hexahydropyridazinyl, etc.
[0177] In this application, the term "heterocyclic alkenyl" refers to a partially unsaturated "heterocyclic group" as defined above, comprising 3-20 ring atoms, wherein one, two, three, or more ring atoms are selected from N, O, or S, and the remaining ring atoms are C. The heterocyclic alkenyl group may optionally be substituted by one or more substituents described in this invention. Preferably, it comprises 4-12 ring atoms (4-12-membered heterocyclic alkenyl), more preferably 5-10 ring atoms (5-10-membered heterocyclic alkenyl), or 5-8 ring atoms (5-8-membered heterocyclic alkenyl), 4-8 ring atoms (4-8-membered heterocyclic alkenyl), or 5-6 ring atoms (5-6-membered heterocyclic alkenyl), or 7 ring atoms (7-membered heterocyclic alkenyl). The number of heteroatoms is preferably 1-4, more preferably 1-3 (i.e., 1, 2, or 3).
[0178] In this application, the term "monocyclic" means, either alone or as part of other substituents, a group that can be saturated, unsaturated or partially saturated and has only one ring, and can be a carbocyclic (all ring atoms are carbon atoms) or a heterocyclic (in addition to carbon atoms, the ring atoms include, for example, 1, 2 or 3 heteroatoms, such as N, O or S).
[0179] In this application, the term "bicyclic" means a group having two connecting rings. A bicyclic ring can be a carbocyclic ring (all ring atoms are carbon atoms) or a heterocyclic ring (in addition to carbon atoms, the ring atoms include, for example, one, two, or three heteroatoms, such as N, O, or S). Both rings can be aliphatic (e.g., naphthane and norbornane), or aromatic (e.g., naphthalene), or a combination of aliphatic and aromatic (e.g., tetrahydronaphthalene). Bicyclic rings include (a) spirocyclic compounds in which the two rings share only one single atom (the spiro atom, which is typically a quaternary carbon). Examples of spirocyclic compounds include, but are not limited to:
[0180] It also includes spirocyclic alkyl groups that share a spiro atom with a heterocyclic alkyl group, and non-limiting examples include:
[0181] (b) Fused bicyclic compounds in which the two rings share two adjacent atoms. In other words, the rings share a single covalent bond, i.e., the bridgehead atoms are directly connected (e.g., α-thuenene and naphthane). Examples of fused bicyclic compounds include, but are not limited to:
[0182] (c) Bridged bicyclic compounds, wherein the two rings share three or more atoms and are separated by a bridge containing at least one atom. For example, norbornane, also known as bicyclic [2.2.1]heptane, can be considered as a pair of cyclopentane rings, each ring sharing three of its five carbon atoms. Examples of bridged bicyclic compounds include, but are not limited to:
[0183] In this application, the term "halogen" or "halogen" refers to fluorine, chlorine, bromine, and iodine, either alone or as part of other substituents.
[0184] Furthermore, it should be noted that, unless otherwise explicitly stated, the descriptive phrase "...independently" used in this invention should be interpreted broadly, meaning that the described individuals are independent of each other and can independently be the same or different specific groups. More specifically, the descriptive phrase "...independently" can mean either that the specific options expressed by the same symbols in different groups do not affect each other, or that the specific options expressed by the same symbols in the same group do not affect each other.
[0185] Unless otherwise specified, the term "patient" means any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses, or primates, with human being being the most preferred.
[0186] Unless otherwise specified, the terms "comprising" or "including" are open-ended expressions, meaning they include the contents specified in this invention but do not exclude other aspects.
[0187] Unless otherwise specified, the term “therapeutic effective amount” means the amount of an active compound or drug that researchers, veterinarians, physicians or other clinicians are looking for in a tissue, system, animal, individual or human to elicit a biological or medical response, including one or more of the following: (1) prevention of disease: for example, prevention of disease, disorder or condition in an individual who is susceptible to disease, disorder or condition but has not yet experienced or developed the pathology or symptoms of the disease. (2) suppression of disease: for example, suppression of disease, disorder or condition in an individual who is experiencing or developing the pathology or symptoms of the disease (i.e., preventing the further development of the pathology and / or symptoms). (3) relief of disease: for example, relief of disease, disorder or condition in an individual who is experiencing or developing the pathology or symptoms of the disease (i.e., reversal of the pathology and / or symptoms).
[0188] The term "treatment" and other similar synonyms used in this article include the following meanings:
[0189] (i) To prevent the occurrence of disease or condition in mammals, especially when such mammals are susceptible to the disease or condition but have not yet been diagnosed with it;
[0190] (ii) To suppress a disease or symptom, that is, to curb its development;
[0191] (iii) To alleviate the disease or symptom, that is, to cause the condition of the disease or symptom to subside; or,
[0192] (iv) To alleviate the symptoms caused by the disease or condition.
[0193] The abbreviations in this invention are defined as follows: NaBH(OAc)3 represents sodium triacetoxyborohydride; DCM represents dichloromethane; MeOH represents methanol; DMAP represents 4-dimethylaminopyridine; TBDPSCl represents tert-butyldiphenylchlorosilane; THF represents tetrahydrofuran; LAH represents lithium aluminum hydride; PE represents petroleum ether; EA represents ethyl acetate; NaOH represents sodium hydroxide; PCC represents pyridinium chlorochromate; n-BuLi represents n-butyllithium; TBAF represents tetrabutylammonium fluoride; CDI represents N,N-carbazyl diimidazole; MTBE represents methyl tert-butyl ether; Boc represents tert-butyl carbonyl; HCl represents hydrochloric acid; MsOH represents methyl Sulfonic acid; TEA represents triethanolamine; Tol represents toluene; Tf2O represents trifluoromethanesulfonic anhydride; DCE represents dichloroethane; LiAlH4 represents lithium aluminum hydride; NaOH represents sodium hydroxide; CHCl3 represents chloroform; Mn2O represents manganese dioxide; MsCl represents methanesulfonyl chloride; Et3N represents triethylamine; MeCN represents acetonitrile; MoMBr represents bromomethyl methyl ether; LiTMP represents lithium tetramethylpiperidine; Pd(dppf)Cl2 represents [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride; CMBP represents 2-(tributylphosphino)acetonitrile; DME represents 1,2-dimethoxyethane; cataCXium A Pd G3 represents third-generation Buchwald-type palladium precatalyst; DMF represents N,N-dimethylformamide; t-BuOK represents potassium tert-butoxide; Trt represents triphenylmethyl; Bn represents benzyl; TsOH represents p-toluenesulfonic acid. Beneficial effects
[0194] According to embodiments of the present invention, the present invention has at least one of the following technical effects:
[0195] This invention provides novel compounds, their tautomers, stereoisomers, or pharmaceutically acceptable salts, exhibiting excellent pharmacokinetic properties, efficacy, and drug-likeness. These compounds can effectively treat infections and diseases caused by mammalian bacteria, particularly infections caused by Neisseria gonorrhoeae or uncomplicated urinary tract infections. The compounds of this invention exhibit strong inhibitory activity against infections caused by mammalian bacteria. Specifically, the compounds of this invention show significant inhibitory activity against Escherichia coli and Staphylococcus aureus. Detailed Implementation
[0196] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that the following description is merely the most preferred embodiment of the present invention and should not be considered as a limitation on the scope of protection of the present invention. Based on a full understanding of the present invention, experimental methods in the following embodiments that do not specify specific conditions are generally performed under conventional conditions or as recommended by the manufacturer. Those skilled in the art can make non-essential modifications to the technical solutions of the present invention, and such modifications should be considered to be included within the scope of protection of the present invention.
[0197] Example 1: Preparation of target compound 1
[0198] (2R)-2-[(4-{[(3,4-dihydro-2H-2,4-methylenepyrano[2,3-c]pyridin-6-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (target compound 1)
[0199] The synthetic route for compound 1 is shown below:
[0200] Step 1: Synthesis of cis-3-(tert-butyl(diphenyl)silyl)oxocyclobutane carboxylate methyl ester (1f-2)
[0201] Methyl cis-3-hydroxycyclobutanecarboxylate (1f-1) (15 g, 115.26 mmol) and imidazole (15.69 g, 230.52 mmol) were dissolved in DCM (200 mL) at 25 °C. DMAP (1.41 g, 11.53 mmol) was added, followed by dropwise addition of TBDPSCl (42.77 g, 155.60 mmol) to the reaction mixture. The reaction mixture was stirred at 25 °C for 1 hour. LC-MS showed that the starting materials were not completely reacted. The reaction solution was diluted with water (200 mL), extracted twice with DCM (200 mL), the organic phases were combined, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to obtain the crude product. This crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate (V / V) = 50:1-10:1, gradient elution) to obtain the product methyl cis-3-(tert-butyl(diphenyl)silyl)oxocyclobutanecarboxylate (1f-2) (40.30 g, 109.35 mmol, yield 94.87%).
[0202] Step 2: Synthesis of cis-(3-(tert-butyl(diphenyl)silyl)oxocyclobutyl)methanol (1f-3)
[0203] Methyl cis-3-(tert-butyl(diphenyl)silyl)oxocyclobutanecarboxylate (1f-2) (40 g, 108.54 mmol) was dissolved in THF (500 mL) at 0 °C. LAH (6.19 g, 162.80 mmol) was added slowly in portions. The reaction mixture was stirred at 25 °C for 1 hour. TLC (PE / EA = 10 / 1) showed complete reaction of the starting material. The reaction mixture was cooled to 0 °C, and 6 mL of water was added dropwise while releasing gas. Then, 6 mL of 15% NaOH aqueous solution was added dropwise, followed by 18 mL of water. Finally, anhydrous magnesium sulfate (40 g) was added, and the mixture was stirred for half an hour before filtration. The filter cake was soaked in THF (80 mL) and stirred for half an hour before filtration again. This operation was repeated twice. All filtrates were combined and evaporated to dryness to obtain the crude product cis-(3-(tert-butyl(diphenyl)silyl)oxocyclobutyl)methanol (1f-3) (35.00 g). This crude product was used directly in the next step.
[0204] Step 3: Synthesis of cis-3-(tert-butyl(diphenyl)silyl)oxocyclobutaneformaldehyde (1f-4)
[0205] cis-(3-(tert-butyl(diphenyl)silyl)oxocyclobutyl)methanol (1f-3) (35 g, 102.78 mmol) was dissolved in DCM (600 mL) at 0 °C, and PCC (33.23 g, 154.17 mmol) was added in portions. The reaction mixture was stirred at 20 °C for 3 hours. TLC (PE / EA = 6 / 1) showed that the starting material was not completely reacted. The reaction mixture was directly filtered and purified by silica gel column chromatography (petroleum ether:ethyl acetate (V / V) = 50:1-10:1, gradient elution) to give the product cis-3-(tert-butyl(diphenyl)silyl)oxocyclobutaneformaldehyde (1f-4) (28.00 g, 82.71 mmol, yield 80.48%).
[0206] 1 H-NMR(400MHz,Chloroform-D)δ9.63(d,J=3.0Hz,1H),7.66-7.61(m,4H),7.45-7.36( m,6H),4.27-4.20(m,1H),2.54-2.45(m,1H),2.34-2.20(m,4H),1.05(d,J=14.8Hz,9H)
[0207] Step 4: Synthesis of cis-tert-butyldiphenyl(3-vinylcyclobutoxy)silane (1f-5)
[0208] Methyl(triphenyl)phosphonium bromide (31.02 g, 86.85 mmol) was dissolved in 500 mL of THF at 0 °C. n-BuLi (2.5 M, 39.70 mL) was added, and the reaction mixture was stirred at 25 °C for 1 hour. The mixture was then cooled to -60 °C, and cis-3-(tert-butyl(diphenyl)silyl)oxocyclobutaneformaldehyde (1f-4) (28 g, 82.71 mmol) in 500 mL of THF was added dropwise to the reaction mixture. The reaction mixture was then allowed to warm naturally to 25 °C and stirred for 16 hours. TLC (PE / EA = 10 / 1) showed that the starting material reacted completely. The reaction mixture was directly mixed with silica gel and purified by silica gel column chromatography (petroleum ether: ethyl acetate (V / V) = 50:1-10:1, gradient elution) to give the product cis-tert-butyldiphenyl(3-vinylcyclobutoxy)silane (1f-5) (21.00 g, 62.40 mmol, yield 75.44%).
[0209] Step 5: Synthesis of cis-3-vinylcyclobutanol (1f-6)
[0210] cis-tert-butyldiphenyl(3-vinylcyclobutoxy)silane (1f-5) (21 g, 62.40 mmol) was dissolved in THF (191.09 mL) at 0 °C, and TBAF (1.0 M, 62.40 mL) was added. The reaction mixture was stirred at 20 °C for 2 hours. TLC (PE / EA = 5 / 1) showed that the starting material was completely reacted. The reaction mixture was directly evaporated to dryness to give a crude product, which was purified by silica gel column chromatography (petroleum ether:ethyl acetate (V / V) = 10:1-2:1, gradient elution) to give the product cis-3-vinylcyclobutanol (1f-6) (5.10 g, 51.97 mmol, yield 83.28%).
[0211] 1 H-NMR(400MHz,Chloroform-D)δ6.00-5.83(m,1H),5.03-4.91(m,2H),4.19-4.12(m,1H),2.55-2.48(m,2H),2.42-2.31(m,1H),1.78-1.70(m,2H)
[0212] Step 6: Synthesis of cis-(3-vinylcyclobutyl)2-(tert-butylcarbonylamino)acetate (1f-8)
[0213] At 25°C, CDI (8.21 g, 57.05 mmol) and MTBE (100 mL) were added to a 500 mL reaction flask, heated to 40°C, and then a Boc-glycine (1f-7) (9.99 g, 57.05 mmol) MTBE (100 mL) solution was added with stirring. The mixture was stirred at 40°C for 0.5 hours. Finally, 3-vinylcyclobutanol (5.09 g, 51.86 mmol) was added over 20 minutes, and the reaction was continued at 40°C with stirring for 2 hours. LCMS showed that the starting material reacted completely. The reaction solution was allowed to cool naturally to room temperature, and 1N HCl (125 mL) was added to separate the layers. The organic phase was washed successively with 1N HCl (125 mL) and water (125 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain the crude product cis-(3-vinylcyclobutyl)2-(tert-butylcarbonylamino)acetate (1f-8) (11.5 g, crude product).
[0214] 1 H-NMR (400MHz, Chloroform-D) δ5.88-5.73(m,1H),5.07-4.95(m,3H),3.92(dd,J=14.2, 5.6Hz,1H),2.17-2.07(m,2H),1.73(t,J=7.4Hz,1H),1.65(t,J=7.4Hz,1H),1.44(s,9H)
[0215] LC-MS, M / Z (ESI): 266.3 (M+H) + .
[0216] Step 7: Synthesis of cis-2-oxo-2-((2-oxo-2-(3-vinylcyclobutyl)ethyl)amino)acetic acid methyl ester (1f-10)
[0217] At 25°C, methanesulfonic acid (8.45 g, 56.30 mmol) was added to a toluene (100 mL) solution of cis-3-vinylcyclobutyl)-2-(tert-butylcarbonylamino)acetate (1f-8) (11.5 g, crude). After addition, the reaction mixture was stirred at 40°C for 2 hours. The mixture was then cooled to 20°C and transferred to a reaction flask containing dimethyl oxalate (1f-9) (6.38 g, 54.05 mmol), maintaining the internal temperature at 20°C while stirring. TEA (9.12 g, 90.09 mmol) was then added to the mixture and stirred for 2 hours. LC-MS showed complete reaction of the starting material. Water (100 mL) was added, the mixture was separated, the organic phase was dried, filtered, and concentrated to give the crude product. The crude product was purified by silica gel column chromatography (petroleum ether:tetrahydrofuran (V / V) = 10:0-5:1, gradient elution) to give the compound cis-2-oxo-2-((2-oxo-2-(3-vinylcyclobutyl)ethyl)amino)acetic acid methyl ester (1f-10) (7.50 g, 31.09 mmol, yield 69.02%).
[0218] 1 H-NMR(400MHz,Chloroform-D)δ7.54(s,1H),5.92-5.83(m,1H),5.03-4.95( m,3H),4.11-4.05(m,2H),3.92(s,3H),2.63-2.53(m,3H),1.99-1.92(m,2H).
[0219] LC-MS, M / Z (ESI): 264.3 (M+23) + .
[0220] Step 8: Synthesis of methyl 3,4-dihydro-2H-2,4-methylbenzo(2,3-c)pyridine-6-carboxylate (1f-11)
[0221] At 20°C, trifluoromethanesulfonic anhydride (11.40 g, 40.42 mmol) was added dropwise to a solution of methyl cis-2-oxo-2-((2-oxo-2-(3-vinylcyclobutyl)ethyl)amino)acetate (1f-10) (6.5 g, 26.94 mmol) and pyridine (8.94 g, 113.07 mmol) in 100 mL of dichloroethane. The reaction mixture was stirred at room temperature for 6 hours. LC-MS showed that the starting material was completely reacted. A 20 wt% aqueous sodium acetate solution (100 mL) was slowly added. The reaction was quenched, and the mixture was extracted with DCM (50 mL). The aqueous phase was extracted twice with DCM (50 mL). The combined organic phases were washed successively with water (100 mL) and 10 wt% citric acid (100 mL). The organic phase was dried, filtered, and concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel column chromatography (petroleum ether:tetrahydrofuran (V / V) = 10:0-5:1, gradient elution) to give compound methyl 3,4-dihydro-2H-2,4-methylno(2,3-c)pyridine-6-carboxylate (1f-11) (300.00 mg, 1.46 mmol, yield 5.43%).
[0222] LC-MS, M / Z (ESI): 206.2 (M+H) + .
[0223] Step 9: Synthesis of (3,4-dihydro-2H-2,4-methyl-(2,3-c)pyridin-6-yl)methanol (1f-12)
[0224] At 0 °C, lithium aluminum hydride (59.51 mg, 1.75 mmol) was added in portions to a THF (10 mL) solution of methyl 3,4-dihydro-2H-2,4-methylno(2,3-c)pyridin-6-carboxylate (1f-11) (300.00 mg, 1.46 mmol). After addition, the mixture was stirred at 0 °C for 2 hours. LC-MS showed that the starting material reacted completely. The reaction was quenched at 0 °C by the slow addition of water (0.1 mL), 15% NaOH aqueous solution (0.1 mL), and water (0.3 mL), followed by the addition of anhydrous magnesium sulfate and stirring. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give crude product (3,4-dihydro-2H-2,4-methylno(2,3-c)pyridin-6-yl)methanol (1f-12) (220 mg, crude product).
[0225] LC-MS, M / Z (ESI): 178.2 (M+H) + .
[0226] Step 10: Synthesis of 3,4-dihydro-2H-2,4-methylpyrano(2,3-c)pyridine-6-carboxaldehyde (1f)
[0227] At room temperature, manganese dioxide (1.08 g, 12.42 mmol) was added to a chloroform (5 mL) solution of (3,4-dihydro-2H-2,4-methyl-(2,3-c)pyridin-6-yl)methanol (1f-12) (220 mg, crude). The mixture was stirred at 50 °C for 2 hours after addition. LC-MS showed complete reaction of the starting material. The reaction mixture was filtered, and the filtrate was concentrated under pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether:ethyl acetate (V / V) = 10:0-5:1, gradient elution) to give compound 3,4-dihydro-2H-2,4-methylpyrano(2,3-c)pyridin-6-carboxaldehyde (1f) (50.80 mg, 289.98 μmol, yield 23.36%).
[0228] 1 H-NMR(400MHz,Chloroform-D)δ9.96(s,1H),8.29(s,1H),7.72(s,1H),5.26-5.22(m,1H),3.49(q,J=5.6Hz,1H),2.56-2.51(m,2H),1.65-1.61(m,2H)
[0229] LC-MS, M / Z (ESI): 176.0 (M+H) + .
[0230] Step 11: Synthesis of [(2S)-3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-2-yl]methylmethanesulfonate (1b)
[0231] (2S)-2-(hydroxymethyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (1a) (100 mg, 0.46 mmol) and dichloromethane (5 mL) were placed in a reaction flask and purged three times with argon gas. Triethylamine (93 mg, 0.92 mmol) was then added. Methylsulfonyl chloride (68 mg, 0.59 mmol) was added at 0 °C, and the mixture was stirred at 0 °C for 0.5 hours. Water (5 mL) and saturated sodium bicarbonate aqueous solution (10 mL) were added to the reaction solution, and the mixture was extracted with (dichloromethane:methanol = 5:1) (10 mL × 5). The organic phase was then dried over anhydrous sodium sulfate, filtered and concentrated to give compound [(2S)-3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-2-yl]methyl methanesulfonate (1b) (130 mg, yield 95.1%).
[0232] LC-MS, M / Z (ESI): 298.3 [M+H] +
[0233] Step 12: Synthesis of tert-butyl(1-{[(2R)-3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-2-yl]methyl}piperidin-4-yl)carbamate (1c)
[0234] [(2S)-3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-2-yl]methyl methanesulfonate (1b) (130 mg, 0.44 mmol) and piperidin-4-ylcarbamate tert-butyl ester (1e) (175 mg, 0.87 mmol) were placed in a reaction flask, and acetonitrile (3 mL) and pyridine (104 mg, 1.3 mmol) were added. The reaction mixture was stirred at 85 °C for 16 hours. The reaction solution was concentrated under reduced pressure, and the crude product was dissolved in dichloromethane (10 mL). It was washed with saturated sodium bicarbonate solution (10 mL), and the organic phase was dried over anhydrous sodium sulfate. After filtration and concentration, the crude product was purified by silica gel column chromatography (dichloromethane:methanol (V / V) = 100:1–10:1) to give the compound tert-butyl(1-{[(2R)-3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-2-yl]methyl}piperidin-4-yl)carbamate (1c) (100 mg, yield 57.0%).
[0235] LC-MS, M / Z (ESI): 402.3 [M+H] +
[0236] Step 13: Synthesis of (2R)-2-[(4-aminopiperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (1d)
[0237] Tert-butyl (1-{[(2R)-3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-2-yl]methyl}piperidin-4-yl) carbamate (1c) (100 mg, 0.25 mmol) was dissolved in 1,4-dioxane (1.5 mL), followed by the addition of hydrogen chloride / 1,4-dioxane (1.5 mL, 4 M) solution, and the reaction was carried out at 20 °C for 2 hours. The reaction solution was concentrated under reduced pressure to give (2R)-2-[(4-aminopiperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (1d) hydrochloride (90 mg, 100% yield).
[0238] LC-MS, M / Z (ESI): 302.4 [M+H] +
[0239] Step 14: Synthesis of (2R)-2-[(4-{[(3,4-dihydro-2H-2,4-methylenepyrano[2,3-c]pyridin-6-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione(1)
[0240] (2R)-2-[(4-aminopiperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (1d) hydrochloride (80 mg, 0.27 mmol) and 3,4-dihydro-2H-2,4-methylenepyrano[2,3-c]pyridine-6-carboxaldehyde (1f) (36.8 mg, 0.21 mmol) were dissolved in dichloromethane (3 mL) and methanol (0.6 mL). Triethylamine (81 mg, 0.8 mmol) was added, and the mixture was stirred at room temperature for 15 minutes. Then, 4A molecular sieves were added and the mixture was stirred for 0.5 hours. Sodium triacetoxyborohydride (572 mg, 2.7 mmol) was added in portions, and the reaction mixture was reacted at 20 °C for 3 hours. Add 5 mL of dichloromethane to the reaction solution, quench with 10 mL of saturated sodium bicarbonate solution, and then extract with (dichloromethane:methanol = 5:1) (10 mL × 3). The organic phase is dried over anhydrous sodium sulfate, filtered and concentrated, and the residue is purified by silica gel column chromatography (dichloromethane:methanol (V / V) = 1:0-5:1, ammonia) to obtain (2R)-2-[(4-{[(3,4-dihydro-2H-2,4-methylenepyrano[2,3-c]pyridin-6-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (1).
[0241] LC-MS, M / Z (ESI): 461.4 [M+H] +
[0242] 1H NMR (600MHz, DMSO-d6) δ7.99(s,1H),7.85(d,J=9.6Hz,1H),7.73(s,1H),7.19(s,1H),6.25(d,J=9.6Hz,1H),5.14( dd,J=9.2,3.6Hz,1H),5.07-4.99(m,1H),4.36-4.28(m,1H),4.23(dd,J=11.2,4.8Hz,1H),3.75(s,2H),3.39(dd,J= 11.2,5.4Hz,3H),2.97-2.89(m,2H),2.78(dd,J=12.8,9.2Hz,1H),2.61(d,J=10.8Hz,1H),2.49-2.46(m,1H),2.18 (t,J=10.8Hz,1H),2.06(t,J=10.8Hz,1H),1.79(dd,J=26.4,12.0Hz,2H),1.45-1.38(m,2H),1.22(d,J=9.2Hz,2H).
[0243] Example 2: Preparation of target compound 2
[0244] (2R)-2-[(4-{[(2'H-spiro[cyclopropane-1,3'-furano[2,3-c]pyridin]-5'-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (target compound 2)
[0245] The synthetic route for compound 2 is shown below:
[0246] Step 1: Synthesis of 2-chloro-5-(methoxymethoxy)pyridine (2a-2)
[0247] The starting material 6-chloropyridin-3-ol (80 g, 617.55 mmol) (2a-1) was dissolved in THF (700 mL). Then, NaH (37.05 g, 926.32 mmol, 60% purity) was added in portions at 0 °C, and the reaction mixture was stirred for 1 h. Next, MoMBr (84.89 g, 679.30 mmol, 55.44 mL) was added to the reaction system, and the reaction mixture was stirred for another 16 h. After the reaction was complete, the reaction mixture was monitored by TLC. Once most of the starting material had reacted completely, the reaction mixture was quenched with water (2 L) in an ice bath and stirred for 10 min. Then, a saturated NaHCO3 solution (2 L) was added and stirred for 30 min. Extraction was performed using EA (1 L * 3). The combined organic extracts were washed with saturated brine (2 L), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether:tetrahydrofuran (V / V) = 10:1-5:1, gradient elution) to give compound 2-chloro-5-(methoxymethoxy)pyridine (2a-2).
[0248] Step 2: Synthesis of 2-chloro-4-iodo-5-(methoxymethoxy)pyridine (2a-3)
[0249] The starting material, 2-chloro-5-(methoxymethoxy)pyridine (2a-2) (75 g, 432.04 mmol), was dissolved in THF (1 L), and the temperature was lowered to -70 °C. Then, n-butyllithium (2.5 M, 224.66 mL) was slowly added, and the reaction was stirred for 1 hour. I2 (115.14 g, 453.64 mmol) was then slowly added. The reaction was carried out at -70 °C with stirring for 16 hours. After the reaction was complete, the reaction mixture was quenched with water (1 L) under ice bath conditions, and then extracted with ethyl acetate (1000 x 2). The combined organic layers were washed with a sodium sulfite solution saturated with 1000 mL x 2, then with brine (1000 mL x 2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was separated by reversed-phase high-performance liquid chromatography (RP-HPLC) using the following method: (column: Welch Xtimate 10um 21.2*250mm; mobile phase: A = water + 0.01% formic acid, B = acetonitrile; gradient 30%-70% B, 2 min) to obtain compound 2-chloro-4-iodo-5-(methoxymethoxy)pyridine (2a-3).
[0250] LC-MS, M / Z (ESI): 300.0 [M+H] + .
[0251] Step 3: Synthesis of 4,4,5,5-tetramethyl-2-(1-vinylcyclopropyl)-1,3,2-dioxaborane (2a-6)
[0252] At 0 °C, n-BuLi (2.5 M, 168.83 mL) was slowly added dropwise to a 1 L THF solution of 2,2,6,6-tetramethylpiperidine (57.64 g, 406.62 mmol, 68.5 mL). After the addition was complete, the mixture was stirred at 0 °C for 30 minutes, then heated to 25 °C and stirred for another 1 h to prepare LiTMP.
[0253] In another reaction flask, bromocyclopropane (2a-5) (41.48 g, 342.76 mmol, 27.62 mL) and 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborane (2a-4) (50 g, 325.29 mmol) were added to THF (850 mL) and cooled to 0 °C. Freshly prepared LiTMP was added to the solution over 30 minutes. The reaction mixture was stirred at 0 °C for 2 hours, then slowly heated to room temperature and stirred for another 16 hours. After the reaction was complete, the reaction mixture was monitored by TLC. The starting material was completely consumed. The reaction mixture was then quenched with saturated ammonium chloride (3000 mL), and the resulting mixture was extracted with ethyl acetate (1000 mL x 2). The combined organic layers were washed with brine (1000 mL x 2), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether:tetrahydrofuran (V / V) = 1:0-100:1, gradient elution) to give compound 4,4,5,5-tetramethyl-2-(1-vinylcyclopropyl)-1,3,2-dioxaborane (2a-6).
[0254] 1 H-NMR (400MHz, CHLOROFORM-D) δ5.76 (dd, J=17.3, 10.7Hz, 1H), 5.14-5.06 (m, 1H) ,4.88-4.80(m,1H),1.23-1.20(m,12H),0.94-0.91(m,2H),0.65(q,J=3.2Hz,2H)
[0255] Step 4: Synthesis of 2-chloro-5-(methoxymethoxy)-4-(1-vinylcyclopropyl)pyridine (2a-7)
[0256] At 25 °C, 4,4,5,5-tetramethyl-2-(1-vinylcyclopropyl)-1,3,2-dioxaborane (2a-6) (12.64 g, 65.11 mmol) and 2-chloro-4-iodo-5-(methoxymethoxy)pyridine (2a-3) (15 g, 50.08 mmol) were dissolved in a mixed solution of dioxane (150 mL) and water (15 mL), and then potassium carbonate (13.84 g, 100.17 mmol) and Pd(dppf)Cl2 (3.67 g, 5.01 mmol) were added. After purging with nitrogen, the reaction mixture was stirred at 100 °C for 16 hours. After the reaction was completed, the reaction solution was filtered and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether: tetrahydrofuran (V / V) = 10:1-3:1, gradient elution) to give compound 2-chloro-5-(methoxymethoxy)-4-(1-vinylcyclopropyl)pyridine (2a-7).
[0257] LC-MS, M / Z (ESI): 239.9 [M+H] + .
[0258] Step 5: Synthesis of 1-(2-chloro-5-(methoxymethoxy)pyridin-4-yl)cyclopropane-1-carboxaldehyde (2a-8)
[0259] The starting material 2-chloro-5-(methoxymethoxy)-4-(1-vinylcyclopropyl)pyridine (2a-7) (4 g, 16.69 mmol) was dissolved in a mixture of THF (50 mL) and water (5 mL). Then, 4-methyl-4-oxomorpholino-4-onium (3.91 g, 33.38 mmol) and potassium osmium tetroxide dihydrate (259.78 mg, 834.39 μmol) were added, and the mixture was stirred at 25 °C for 4 hours. Sodium periodate (8.92 g, 41.72 mmol) was then added, and the mixture was stirred at 25 °C for 16 hours. After the reaction was complete, the reaction was quenched with sodium sulfite solution (50 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic phases were washed with saturated brine (3 x 40 mL) and dried over anhydrous sodium sulfate. The solvent was removed by concentration under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether: tetrahydrofuran (V / V) = 20:1-10:1, gradient elution) to give compound 1-(2-chloro-5-(methoxymethoxy)pyridin-4-yl)cyclopropane-1-carboxaldehyde (2a-8).
[0260] LC-MS, M / Z (ESI): 241.9 [M+H] + .
[0261] Step 6: Synthesis of (1-(2-chloro-5-(methoxymethoxy)pyridin-4-yl)cyclopropyl)methanol (2a-9)
[0262] Sodium borohydride (399.19 mg, 10.55 mmol) was slowly added to a methanol (30 mL) solution of 1-(2-chloro-5-(methoxymethoxy)pyridin-4-yl)cyclopropane-1-carboxaldehyde (2a-8) (1.7 g, 7.03 mmol) at 0 °C, and the mixture was stirred at 25 °C for 16 hours. After the reaction was completed, the reaction was quenched with water (30 mL) at 0 °C and extracted with ethyl acetate (3 x 30 mL). The combined organic phases were washed with saturated brine (50 mL) and dried over anhydrous sodium sulfate. The solvent was removed by filtration under reduced pressure to give the crude product as compound (1-(2-chloro-5-(methoxymethoxy)pyridin-4-yl)cyclopropyl)methanol (2a-9).
[0263] LC-MS, M / Z (ESI): 244.0 [M+H] + .
[0264] Step 7: Synthesis of 6-chloro-4-(1-(hydroxymethyl)cyclopropyl)pyridin-3-ol (2a-10)
[0265] The starting material (1-(2-chloro-5-(methoxymethoxy)pyridin-4-yl)cyclopropyl)methanol (2a-9) (1.6 g, 6.57 mmol) was dissolved in dioxane hydrochloride (4 M, 20 mL), and the reaction was stirred at 25 °C for 16 hours. After the reaction was completed, the reaction mixture was concentrated under reduced pressure to give compound 6-chloro-4-(1-(hydroxymethyl)cyclopropyl)pyridin-3-ol (2a-10).
[0266] LC-MS, M / Z (ESI): 200.0 [M+H] + .
[0267] Step 8: Synthesis of 5'-chloro-2'H-spiro(cyclopropane-1,3'-furano(2,3-c)pyridine) (2a-11)
[0268] The starting material 6-chloro-4-(1-(hydroxymethyl)cyclopropyl)pyridin-3-ol (2a-10) (1.5 g, 7.51 mmol) was dissolved in xylene (15 mL), followed by the addition of 2-(tributylphosphino)acetonitrile (2.72 g, 11.27 mmol). After purging with nitrogen, the reaction was heated to 170 °C and stirred for 1 hour in a microwave reactor. After the reaction was completed, the reaction mixture was concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether:tetrahydrofuran (V / V) = 10:1-5:1, gradient elution) to obtain compound 5'-chloro-2'H-spiro(cyclopropane-1,3'-furano(2,3-c)pyridine) (2a-11).
[0269] LC-MS, M / Z (ESI): 181.9 [M+H] + .
[0270] Step 9: Synthesis of 5'-vinyl-2'H-spiro(cyclopropane-1,3'-furano(2,3-c)pyridine) (2a-12)
[0271] The starting materials 5'-chloro-2'-H-spiro(cyclopropane-1,3'-furano(2,3-c)pyridine)(2a-11) (650 mg, 3.58 mmol) and potassium (vinyl)trifluoroborate (575.28 mg, 4.29 mmol) were dissolved in a mixed solvent of H₂O (2 mL) and DME (10 mL), followed by the addition of cesium carbonate (2.33 g, 7.16 mmol) and cataCXium A Pd G₃ (521.29 mg, 715.79 μmol). After purging with nitrogen, the reaction was carried out in a microwave reactor at 90 °C for 1 hour. After the reaction was complete, water (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic layer was washed with brine (30 mL) and dried over anhydrous sodium sulfate. The solvent was removed by concentration under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether: tetrahydrofuran (V / V) = 10:1-5:1, gradient elution) to give compound 5'-vinyl-2'H-spiro(cyclopropane-1,3'-furano(2,3-c)pyridine) (2a-12).
[0272] LC-MS, M / Z (ESI): 174.0 [M+H] + .
[0273] Step 10: Synthesis of 2'H-spiro(cyclopropane-1,3'-furano(2,3-c)pyridine)-5'-carboxaldehyde (2a)
[0274] The starting material 5'-vinyl-2'H-spiro(cyclopropane-1,3'-furano(2,3-c)pyridine) (2a-12) (280 mg, 1.62 mmol) was dissolved in dichloromethane (20 mL), and then ozone was introduced at -78 °C, and the reaction was stirred for 1 hour. After the reaction was completed, the reaction was quenched with dimethyl sulfide (2 mL). After quenching, the reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether: tetrahydrofuran (V / V) = 10:1-5:1, gradient elution) to obtain compound 2'H-spiro(cyclopropane-1,3'-furano(2,3-c)pyridine)-5'-carboxaldehyde (2a).
[0275] 1 H-NMR(400MHz,CHLOROFORM-D)δ9.95(dd,J=22.7,11.7Hz,1H),8.12(d,J=92.6Hz,1H),7.39(s,1H),1.33-1.13(m,4H)
[0276] LC-MS, M / Z (ESI): 176.0 [M+H] + .
[0277] Step 11: Synthesis of (2R)-2-[(4-{[(2'H-spiro[cyclopropane-1,3'-furano[2,3-c]pyridin]-5'-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione(2)
[0278] (2R)-2-[(4-aminopiperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (1d) (100 mg, 0.3 mmol) was dissolved in methanol (5 mL), and 2'H-spiro(cyclopropane-1,3'-furano(2,3-c)pyridine)-5'-carboxaldehyde (2a) (52 mg, 0.3 mmol) was added. Sodium triacetoxyborohydride (212 mg, 1.0 mmol) was added in portions. The reaction solution was reacted at 60 °C for 2 hours. The crude product was purified by silica gel column chromatography (dichloromethane:methanol (V / V) = 1:1), and after enrichment and concentration, it was purified by preparative chromatography (column: YMC-Triar Prep C18S-12nm S-7μm 50mm*40cm; mobile phase A: 10mM NH4HCO3; mobile phase B: acetonitrile; flow rate: 80mL / min) to obtain (2R)-2-[(4-{[(2'H-spiro[cyclopropane-1,3'-furano[2,3-c]pyridin]-5'-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (2).
[0279] LC-MS, M / Z (ESI): 461.2 [M+H] +
[0280] 1 H NMR (400MHz, DMSO-d6) δ7.94(s,1H),7.85(d,J=9.6Hz,1H),7.72(s,1H),6.91(s,1H),6.25(d, J=9.6Hz,1H),5.07-4.97(m,1H),4.51(s,2H),4.31(dd,J=12.0,9.2Hz,1H),4.23(dd,J=12.0,4 .8Hz,1H),3.65(s,2H),2.99-2.84(m,2H),2.77(dd,J=12.8,8.8Hz,1H),2.57(d,J=11.2Hz,1H) ,2.32(s,1H),2.20-2.11(m,1H),2.08-2.00(m,1H),1.72(t,J=15.6Hz,2H),1.34-1.04(m,7H).
[0281] Example 3: Preparation of target compound 3
[0282] (2R)-2-[(4-{[(2',3'-dihydrospiro[cyclopropane-1,4'-pyrano[2,3-c]pyridine]-6'-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (target compound 3)
[0283] The synthetic route for target compound 3 is shown below:
[0284] Step 1: Synthesis of 2-(1-(2-chloro-5-(methoxymethoxy)pyridin-4-yl)cyclopropyl)ethanol-1-ol (3a-1)
[0285] A boranetetrahydrofuran complex (1M, 109.51 mL) was stirred at 0 °C under a nitrogen atmosphere, followed by dropwise addition of a THF (100 mL) solution of 2-chloro-5-(methoxymethoxy)-4-(1-vinylcyclopropyl)pyridine (2a-7) (10.5 g, 43.81 mmol). Stirring was continued at room temperature for 2.5 h. After cooling, THF / H₂O (200 mL, 1:1 v / v), sodium hydroxide (2M, 87.61 mL), and H₂O₂ (4.97 g, 43.81 mmol, 4.2 mL, 30% purity) were added sequentially to the mixture. The resulting mixture was stirred at 25 °C for 16 h. After the reaction was complete, ethyl acetate (100 mL) was added to the reaction mixture, followed by washing twice with ice / water (100 mL) and a saturated sodium chloride solution (100 mL). The mixture was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel column chromatography (petroleum ether: tetrahydrofuran (V / V) = 10:1-3:1, gradient elution) to give compound 2-(1-(2-chloro-5-(methoxymethoxy)pyridin-4-yl)cyclopropyl)ethanol-1-ol (3a-1).
[0286] LC-MS, M / Z (ESI): 258.0 [M+H] + .
[0287] Step 2: Synthesis of 6-chloro-4-(1-(2-hydroxyethyl)cyclopropyl)pyridine-3-ol (3a-2)
[0288] The starting material 2-(1-(2-chloro-5-(methoxymethoxy)pyridin-4-yl)cyclopropyl)ethanol-1-ol (3a-1) (3 g, 11.64 mmol) was dissolved in dioxane hydrochloride (4 M, 30 mL), and the reaction was stirred at 25 °C for 16 hours. After the reaction was completed, the reaction mixture was concentrated under reduced pressure to give compound 6-chloro-4-(1-(2-hydroxyethyl)cyclopropyl)pyridin-3-ol (3a-2).
[0289] LC-MS, M / Z (ESI): 214.0 [M+H] + .
[0290] Step 3: Synthesis of 6'-chloro-2',3'-dihydrospiro(cyclopropane-1,4'-pyrano(2,3-c)pyridine) (3a-3)
[0291] The starting material 6-chloro-4-(1-(2-hydroxyethyl)cyclopropyl)pyridin-3-ol (3a-2) (4 g, 18.72 mmol) was dissolved in xylene (40 mL), and then 2-(tributylphosphino)acetonitrile (6.78 g, 28.08 mmol) was added. After purging with nitrogen, the reaction was stirred in a microwave reactor at 170 °C for 1 hour. After the reaction was complete, the reaction solution was cooled to 25 °C, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL * 3). The organic layer was washed with brine (50 mL) and dried over anhydrous sodium sulfate. The solvent was removed by concentration under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether:tetrahydrofuran (V / V) = 10:1-5:1, gradient elution) to obtain compound 6'-chloro-2',3'-dihydrospiro(cyclopropane-1,4'-pyrano(2,3-c)pyridine) (3a-3).
[0292] LC-MS, M / Z (ESI): 196.0 [M+H] + .
[0293] Step 4: Synthesis of 6'-vinyl-2',3'-dihydrospiro(cyclopropane-1,4'-pyran(2,3-c)pyridine) (3a-4)
[0294] The starting materials 6'-chloro-2',3'-dihydrospiro(cyclopropane-1,4'-pyrano(2,3-c)pyridine)(3a-3) (1.2 g, 6.13 mmol) and potassium (vinyl)trifluoroborate (985.90 mg, 7.36 mmol) were dissolved in a mixed solvent of H₂O (4 mL) and DME (20 mL), followed by the addition of cesium carbonate (4.00 g, 12.27 mmol) and cataCXium A Pd G₃ (893.38 mg, 1.23 mmol). After purging with nitrogen, the reaction was carried out at 90 °C in a microwave reactor for 1 hour. After the reaction was complete, water (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic layer was washed with saturated brine (30 mL) and dried over anhydrous sodium sulfate. The solvent was removed by concentration under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether: tetrahydrofuran (V / V) = 10:1-5:1, gradient elution) to give compound 6'-vinyl-2',3'-dihydrospiro(cyclopropane-1,4'-pyran(2,3-c)pyridine) (3a-4).
[0295] LC-MS, M / Z (ESI): 187.9 [M+H] + .
[0296] Step 5: Synthesis of 2',3'-dihydrospiro(cyclopropane-1,4'-pyrano(2,3-c)pyridine)-6'-carboxaldehyde (3a)
[0297] The starting material 6'-vinyl-2',3'-dihydrospiro(cyclopropane-1,4'-pyran(2,3-c)pyridine) (3a-4) (520 mg, 3.00 mmol) was dissolved in DCM (20 mL), and then ozone was introduced at -78 °C and the reaction was stirred for 2 hours. After the reaction was completed, the reaction was quenched with dimethyl sulfide (4 mL). After quenching, the reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether:tetrahydrofuran (V / V) = 10:1-5:1, gradient elution) to obtain compound 2',3'-dihydrospiro(cyclopropane-1,4'-pyrano(2,3-c)pyridine)-6'-formaldehyde (3a).
[0298] 1 H-NMR(400MHz,CHLOROFORM-D)δ9.95-9.88(m,1H),8.25(s,1H),7.33(s,1H), 4.47-4.34(m,2H),1.93(t,J=5.1Hz,2H),1.27-1.17(m,2H),1.07-0.96(m,2H)
[0299] LC-MS, M / Z (ESI): 190.0 [M+H] + .
[0300] Step 6: (2R)-2-[(4-{[(2',3'-dihydrospiro[cyclopropane-1,4'-pyrano[2,3-c]pyridine]-6'-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (target compound 3)
[0301] At room temperature, triethylamine (75 mg, 0.75 mmol) was added to a solution of (2R)-2-[(4-aminopiperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (1d) (75 mg, 0.25 mmol) in dichloromethane (4.5 mL) and methanol (4.5 mL). The mixture was stirred at room temperature for 10 minutes, and then acetic acid was added to adjust the solution to a slightly warmer consistency. In an acidic environment, 2',3'-dihydrospiro[cyclopropane-1,4'-pyrano[2,3-c]pyridine]-6'-carboxaldehyde (3a) (47 mg, 0.25 mmol) and 4A molecular sieve (1 g) were added. After stirring for 30 minutes, sodium borohydride acetate (158 mg, 0.75 mmol) was added. Sodium borohydride acetate (158 mg, 0.75 mmol) was added again every hour for four times. The reaction was carried out for 12 hours.
[0302] The reaction was monitored by LCMS. After no raw material remained, saturated sodium bicarbonate aqueous solution (80 mL) was added to the reaction solution until the system was alkaline. The mixture was allowed to stand and separate into layers. The aqueous phase was extracted three times with dichloromethane (100 mL) and methanol (10 mL). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and purified by plate preparation (dichloromethane:methanol = 10:1, 0.1% ammonia) to obtain the target product (2R)-2-[(4-{[(2',3'-dihydrospiro[cyclopropane-1,4'-pyrano[2,3-c]pyridin]-6'-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (3).
[0303] LC-MS, M / Z (ESI): 475.30 [M+H]+
[0304] 1H NMR (400MHz, DMSO) δ7.93(s,1H),7.86(d,J=9.5Hz,1H),7.73(s,1H),6.77(s,1H),6.26(d,J=9.5Hz,1H),5.04 –5.01(m,1H),4.36–4.28(m,1H),4.24(dd,J=10.0,4.7Hz,3H),3.64(s,2H),2.99–2.86(m,2H),2.78(dd,J=12 .6,8.8Hz,1H),2.58(d,J=11.2Hz,1H),2.34(s,1H),2.17(t,J=10.7Hz,1H),2.05(t,J=11.0Hz,1H),1.88–1.8 4(m,2H),1.73(t,J=15.1Hz,2H),1.24(s,1H),1.22–1.13(m,2H),1.10(d,J=6.2Hz,2H),0.97(d,J=6.0Hz,2H).
[0305] Example 4: Preparation of target compound 4
[0306] (2R)-2-[(4-{[(2'-oxo-1',2'-dihydrospiro[cyclopropane-1,3'-pyrrolo[2,3-b]pyridine]-6'-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (target compound 4)
[0307] The synthetic route for compound 4 is shown below:
[0308] Step 1: Synthesis of 6'-chlorospiro(cyclopropane-1,3'-pyrrolo(2,3-b)pyridine)-2'(1'H)-one (4a-2)
[0309] 6-Chloro-1,3-dihydropyrrolo(2,3-b)pyridin-2-one (10.0 g, 59.32 mmol) (4a-1) was dissolved in DMF (100 mL) and cooled to 0 °C. NaH (7.12 g, 296.59 mmol) was carefully added in portions to the reaction flask. The reaction mixture was slowly heated to 25 °C and stirred for 30 minutes. Then, a DMF (10 mL) solution of 1,2-dibromoethane (11.70 g, 62.28 mmol, 5.37 mL) was added dropwise. The reaction mixture was stirred at 25 °C for 16 hours. After the reaction was complete, the reaction solution was cooled to 0 °C, and saturated ammonium chloride (200 mL) was slowly added to quench the reaction mixture. The mixture was extracted with ethyl acetate (100 mL * 2), and the organic phases were combined. The mixture was washed with saturated brine (100 mL * 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether: tetrahydrofuran (V / V) = 5:1-1:1, gradient elution) to give compound 6'-chlorospiro(cyclopropane-1,3'-pyrrolo(2,3-b)pyridine)-2'(1'H)-one (4a-2).
[0310] LC-MS, M / Z(ESI): 195.1[M+H]+.
[0311] Step 2: Synthesis of 6'-vinylspiro(cyclopropane-1,3'-pyrrolo(2,3-b)pyridine)-2'(1'H)-one (4a-3)
[0312] The starting materials 6'-chlorospiro(cyclopropane-1,3'-pyrrolo(2,3-b)pyridine)-2'(1'H)-one (4a-2) (500.0 mg, 2.57 mmol) and potassium trifluoro(vinyl)trifluoroborate (688.27 mg, 5.14 mmol) were dissolved in a mixed solution of H2O (10 mL) and DME (2 mL), and then cesium carbonate (1.67 g, 5.14 mmol) and cataCXium A Pd G3 (374.21 mg, 513.83 μmol) were added. After purging with nitrogen, the reaction was carried out at 85 °C in a microwave reactor with stirring for 1 hour. The reaction was carried out in three parallel pots. After the reaction was completed, the reaction solution was filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: tetrahydrofuran (V / V) = 5:1-1:1, gradient elution) to obtain compound 6'-vinylspiro(cyclopropane-1,3'-pyrrolo(2,3-b)pyridine)-2'(1'H)-one (4a-3).
[0313] LC-MS, M / Z (ESI): 187.3 [M+H] + .
[0314] Step 3: 2'-oxo-1',2'-dihydrospiro(cyclopropane-1,3'-pyrrolo(2,3-b)pyridine)-6'-formaldehyde (4a)
[0315] The starting material 6'-vinylspiro(cyclopropane-1,3'-pyrrolo(2,3-b)pyridine)-2'(1'H)-one (4a-3) (900 mg, 4.83 mmol) was dissolved in dichloromethane (20 mL), and then ozone was introduced at -78°C, and the reaction was stirred for 2 hours. After the reaction was completed, the reaction was quenched with dimethyl sulfide. After quenching, the reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether:tetrahydrofuran (V / V) = 5:1-0:1, gradient elution) to obtain the crude product. The crude product was then separated by preparative high performance liquid chromatography (HPLC). The separation method was as follows: (chromatographic column: Welch Xtimate 10μm 21.2*250mm; mobile phase: A = water + 0.01% formic acid, B = acetonitrile; gradient 15%-50% B, 3 hours) to obtain compound 2'-oxo-1',2'-dihydrospiro(cyclopropane-1,3'-pyrrolo(2,3-b)pyridine)-6'-carboxaldehyde (4a).
[0316] 1 H-NMR (400MHz, DMSO-D6) δ11.53(s,1H),9.88(s,1H),7.60(t,J=7.7Hz,2H),1.81(q,J=3.9Hz,2H),1.67-1.63(m,2H)
[0317] LC-MS, M / Z (ESI): 189.1 [M+H] + .
[0318] Step 4: Synthesis of (2R)-2-[(4-{[(2'-oxo-1',2'-dihydrospiro[cyclopropane-1,3'-pyrrolo[2,3-b]pyridine]-6'-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione(4)
[0319] At room temperature, triethylamine (75 mg, 0.75 mmol) was added to a solution of (2R)-2-[(4-aminopiperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (75 mg, 0.249 mmol) (1 day) in dichloromethane (4.5 mL) and methanol (4.5 mL). The mixture was stirred at room temperature for 10 minutes, and then acetic acid was added to adjust the pH to weakly acidic. Add 2'-oxo-1',2'-dihydrospiro[cyclopropane-1,3'-pyrrolo[2,3-b]pyridine]-6'-carboxaldehyde (4a) (46 mg, 0.249 mmol) and 4A molecular sieve (1 g), stir for 30 minutes, then add sodium borohydride acetate (158 mg, 0.75 mmol), and add sodium borohydride acetate (158 mg, 0.75 mmol) again every 1 hour, for a total of five additions, and react for 12 hours. The reaction was monitored by LCMS. After no raw material remained, saturated sodium bicarbonate aqueous solution (50 mL) was added to the reaction solution. The mixture was allowed to stand and separate into layers. The aqueous phase was extracted three times with dichloromethane (50 mL) and methanol (5 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a concentrate. Hydrochloric acid aqueous solution (~0.6 N) was added to the above concentrate to pH=4~5. The concentrate was purified by high performance liquid chromatography (0.1% ammonium bicarbonate aqueous solution / acetonitrile (V / V)=0~100) to obtain the target product (2R)-2-[(4-{[(2'-oxo-1',2'-dihydrospiro[cyclopropane-1,3'-pyrrolo[2,3-b]pyridin]-6'-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (4).
[0320] LC-MS, M / Z (ESI): 474.50 [M+H] +
[0321] 1H NMR (600MHz, DMSO-d6) δ11.04(s,1H),7.83(d,J=9.6Hz,1H),7.71(s,1H),7.26(d,J=7.6Hz,1H),6.95(d,J=7.6Hz,1H),6.23 (d,J=9.6Hz,1H),5.04-4.96(m,1H),4.32-4.26(m,1H),4.21(dd,J=11.6,4.8Hz,1H),3.68(s,2H),2.92(dd,J=12.8,3.2Hz,1 H),2.87(d,J=10.8Hz,1H),2.75(dd,J=12.8,8.8Hz,1H),2.60-2.53(m,2H),2.35(d,J=18.4Hz,1H),2.14(t,J=10.8Hz,1H),2 .05-1.99(m,1H),1.71(dd,J=25.2,11.6Hz,2H),1.57(dd,J=7.6,3.6Hz,2H),1.46(dd,J=7.6,3.6Hz,2H),1.23-1.11(m,2H).
[0322] Example 5: Preparation of target compound 5
[0323] (2R)-2-[(4-{[(3'H-spiro[cyclopropane-1,2'-[1,4]dioxane-1,2'-[1,4]dioxane-2,3-c]pyridine]-7'-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (target compound 5)
[0324] The synthetic route for compound 5 is shown below:
[0325] Step 1: Synthesis of methyl 2-({5-(benzyloxy)-2-[(triphenylmethoxy)methyl]pyridin-4-yl}oxy)-4-bromobutyrate (5b)
[0326] Potassium carbonate (3.59 g, 26 mmol) and methyl 2,4-dibromobutyrate (6.76 g, 26 mmol) were added sequentially to a DMF (100 mL) solution of 5-(benzyloxy)-2-[(triphenylmethoxy)methyl]pyridin-4-yl]oxy)-4-bromobutyrate (5b) at room temperature. The mixture was stirred at room temperature until the reaction was complete as detected by TLC. After filtration and concentration, the crude product was purified by silica gel column chromatography (petroleum ether:ethyl acetate (V / V) = 100:1-4:1) to give compound methyl 2-({5-(benzyloxy)-2-[(triphenylmethoxy)methyl]pyridin-4-yl}oxy)-4-bromobutyrate.
[0327] LC-MS, M / Z (ESI): 652.2 [M+H] +
[0328] Step 2: Synthesis of methyl 1-({5-(benzyloxy)-2-[(triphenylmethoxy)methyl]pyridin-4-yl}oxy)cyclopropane-1-carboxylic acid (5c)
[0329] Under nitrogen atmosphere at 0°C, potassium tert-butoxide (1.57 g, 14 mmol) was slowly added to a tetrahydrofuran (100 mL) solution of methyl 2-({5-(benzyloxy)-2-[(triphenylmethoxy)methyl]pyridin-4-yl}oxy)-4-bromobutyrate (5b) (8.33 g, 12.8 mmol). The mixture was brought back to room temperature and stirred for 3 hours. After the starting material disappeared as detected by TLC, the mixture was quenched by adding saturated ammonium chloride solution (20 mL) at 0°C. The aqueous phase was separated and combined with ethyl acetate (100 mL × 2). The organic phases were dried with anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate (V / V) = 100:1-4:1) to give compound methyl 1-({5-(benzyloxy)-2-[(triphenylmethoxy)methyl]pyridin-4-yl}oxy)cyclopropane-1-carboxylic acid (5c).
[0330] LC-MS, M / Z (ESI): 572.2 [M+H] +
[0331] Step 3: Synthesis of [1-({5-(benzyloxy)-2-[(triphenylmethoxy)methyl]pyridin-4-yl}oxy)cyclopropyl]methanol (5d)
[0332] Under nitrogen atmosphere at 0 °C, lithium aluminum hydride (0.51 g, 13.4 mmol) was slowly added to a tetrahydrofuran (100 mL) solution of methyl 1-({5-(benzyloxy)-2-[(triphenylmethoxy)methyl]pyridin-4-yl}oxy)cyclopropane-1-carboxylic acid (5c) (5.08 g, 8.9 mmol). The mixture was brought back to room temperature and stirred for 3 hours. After the starting material disappeared as detected by TLC, the mixture was quenched by adding saturated ammonium chloride solution (20 mL) at 0 °C. The mixture was then filtered, concentrated, extracted with ethyl acetate, and the organic phases were separated and combined. The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate (V / V) = 100:1-2:1) to give compound [1-({5-(benzyloxy)-2-[(triphenylmethoxy)methyl]pyridin-4-yl}oxy)cyclopropyl]methanol (5d).
[0333] LC-MS, M / Z (ESI): 544.2 [M+H] +
[0334] Step 4: Synthesis of 4-{[1-(hydroxymethyl)cyclopropyl]oxy}-6-[(triphenylmethoxy)methyl]pyridine-3-ol (5e)
[0335] To a methanol (50 mL) solution of [1-({5-(benzyloxy)-2-[(triphenylmethoxy)methyl]pyridin-4-yl}oxy)cyclopropyl]methanol (5d) (3.4 g, 6.3 mmol), 10% palladium on carbon (1.7 g) was added. The mixture was stirred for 10 hours at room temperature under a hydrogen atmosphere. After the starting material disappeared as detected by TLC, the mixture was filtered and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate (V / V) = 100:1-0:1) to give compound 4-{[1-(hydroxymethyl)cyclopropyl]oxy}-6-[(triphenylmethoxy)methyl]pyridin-3-ol (5e).
[0336] LC-MS, M / Z (ESI): 454.2 [M+H] +
[0337] Step 5: Synthesis of 7'-[(triphenylmethoxy)methyl]-3'H-spiro[cyclopropane-1,2'-[1,4]dioxane-hexeno[2,3-c]pyridine] (5f)
[0338] Triphenylphosphine (1.78 g, 6.8 mmol) and diethyl azodicarbonate (1.3 g, 7.4 mmol) were added sequentially to a solution of 4-{[1-(hydroxymethyl)cyclopropyl]oxy}-6-[(triphenylmethoxy)methyl]pyridin-3-ol (5e) (2.8 g, 6.2 mmol) in dichloromethane (50 mL) under nitrogen atmosphere at 0 °C. The mixture was then stirred at room temperature for 3 hours. After the starting material disappeared as detected by TLC, dichloromethane was added for dilution. The mixture was washed sequentially with water and saturated brine. The organic phases were separated and combined, dried with anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate (V / V) = 100:1-1:1) to give compound 7'-[(triphenylmethoxy)methyl]-3'H-spiro[cyclopropane-1,2'-[1,4]dioxane-hexeno[2,3-c]pyridine] (5f).
[0339] LC-MS, M / Z (ESI): 436.2 [M+H] +
[0340] Step 6: Synthesis of (3'H-spiro[cyclopropane-1,2'-[1,4]dioxane[2,3-c]pyridine]-7'-yl)methanol (5g)
[0341] To a methanol (20 mL) solution of 7'-[(triphenylmethoxy)methyl]-3'H-spiro[cyclopropane-1,2'-[1,4]dioxane[2,3-c]pyridine](5f) (1.35 g, 3.1 mmol), p-toluenesulfonic acid (0.8 g, 4.65 mmol) was added. The mixture was stirred at 75 °C for 3 hours. After TLC detection showed the disappearance of the starting material, the mixture was brought to room temperature and concentrated. The crude product was then purified by silica gel column chromatography (petroleum ether: ethyl acetate (V / V) = 100:1-0:1) to obtain compound (3'H-spiro[cyclopropane-1,2'-[1,4]dioxane[2,3-c]pyridine]-7'-yl)methanol (5 g).
[0342] LC-MS, M / Z (ESI): 194.1 [M+H] +
[0343] Step 7: Synthesis of 3'H-spiro[cyclopropane-1,2'-[1,4]dioxane-[2,3-c]pyridine]-7'-carbaldehyde (5h)
[0344] To a solution of (3'H-spiro[cyclopropane-1,2'-[1,4]dioxane[2,3-c]pyridine]-7'-yl)methanol (5 g) (600 mg, 3.1 mmol) in 30 mL of dichloromethane, p-manganese dioxide (1.35 g, 15.5 mmol) was added. The mixture was stirred at room temperature for 12 hours. After the starting material disappeared as detected by TLC, the mixture was filtered and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate (V / V) = 100:1-3:1) to give compound 3'H-spiro[cyclopropane-1,2'-[1,4]dioxane[2,3-c]pyridine]-7'-carboxaldehyde (5 h).
[0345] LC-MS, M / Z (ESI): 192.0 [M+H] +
[0346] Step 8: Synthesis of (2R)-2-[(4-{[(3'H-spiro[cyclopropane-1,2'-[1,4]dioxane-1,2'-[1,4]dioxane-2,3-c]pyridine]-7'-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione(5)
[0347] (2R)-2-[(4-aminopiperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (1d) (100 mg, 0.3 mmol, hydrochloride) was dissolved in methanol (5 mL), and 3'H-spiro[cyclopropane-1,2'-[1,4]dioxane-[2,3-c]pyridine]-7'-carboxaldehyde (5h) (57 mg, 0.3 mmol) was added. Sodium triacetoxyborohydride (212 mg, 1.0 mmol) was added in portions. The reaction solution was reacted at 60 °C for 2 hours. The crude product was purified by silica gel column chromatography (dichloromethane:methanol (V / V) = 1:1), and after enrichment and concentration, it was purified by preparative chromatography (column: YMC-Triar Prep C18S-12nm S-7μm 50mm*40cm; mobile phase A: 10mM NH4HCO3; mobile phase B: acetonitrile; flow rate: 80mL / min) to obtain (2R)-2-[(4-{[(3'H-spiro[cyclopropane-1,2'-[1,4]dioxane-1,2'-[1,4]dioxane-2,3-c]pyridin]-7'-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (5).
[0348] LC-MS, M / Z (ESI): 477.2 [M+H] +
[0349] 1 H NMR (400MHz, DMSO-d6) δ8.05(s,1H),7.84(d,J=9.6Hz,1H),7.72(s,1H),6.89(s,1H),6.25(d,J=9. 6Hz,1H),5.08-4.96(m,1H),4.31(dd,J=12.0,9.2Hz,1H),4.27-4.18(m,3H),3.63(s,2H),2.94(dd ,1H),2.91-2.84(m,1H),2.77(dd,1H),2.62-2.54(m,1H),2.38-2.26(m,1H),2.21-2.11(m,1H),2. 07-1.99(m,1H),1.70(d,J=15.6Hz,2H),1.23(s,1H),1.22-1.09(m,2H),1.03(t,2H),0.90(t,2H).
[0350] The preparation methods for the following compounds are described in Examples 1-5:
[0351] For the preparation method of the control compound, please refer to compound 39 in patent WO2008128942A1. The specific structural formula is as follows:
[0352] Biological testing
[0353] Experimental Example 1: Determination of Minimum Inhibitory Concentration (MIC) of Antibiotics
[0354] The in vitro antibacterial activity of the antibiotics was determined using a minimum inhibitory concentration (MIC) assay. The test bacteria were *Escherichia coli* (Top 10, BNCC353819) and *Staphylococcus aureus* (BNCC238481), and the culture medium was sterile cationic-adjusted M-HII broth (BD, catalog number: 212322). The test compound was dissolved in cationic-adjusted M-HII broth to prepare a maximum working concentration of 64 μg / mL. This solution was then serially diluted twofold with the culture medium. The diluted media were transferred to sterile 96-well plates (100 μL per well), with control wells containing no compound. Subsequently, the bacteria were reconstituted with the culture medium to a final concentration of ~1 x 10⁻⁶. 6Add 100 μL of the CFU / mL working solution to each well of a 96-well plate, and simultaneously set up blank wells free of both the compound and bacteria. After mixing, incubate the 96-well plate at 37°C for 16 hours. After incubation, transfer the 96-well plate to a microplate reader (Molecular Devices, SpectraMax iD5) and measure the absorbance at OD 600 of each well. Calculate the bacterial growth inhibition rate at different compound concentrations. The lowest concentration at which the compound inhibits bacterial growth by >80% is the minimum inhibitory concentration (MIC) of that compound.
[0355] Table 1 MIC data for compounds
[0356] Experimental results show that the compounds of this invention have significant inhibitory effects on Escherichia coli and Staphylococcus aureus.
[0357] Experimental Example 2: Rat Pharmacokinetic Test
[0358] Pharmacokinetic studies were conducted on male SD rats (180-240g) that had been fasted overnight. Three rats were administered the drug 10mg / kg orally via gavage. Blood samples were collected before administration and at 15, 30 minutes, 1, 2, 4, 8, and 24 hours after administration. Urine samples were also collected at different time points. Blood samples (6800g) were centrifuged at 2-8℃ for 6 minutes to collect plasma, which was then stored together with urine samples at -80℃. Plasma and urine samples from each time point were mixed with acetonitrile solution containing an internal standard, vortexed, centrifuged, and the supernatant was mixed with water. An appropriate amount of the mixture was analyzed by LC-MS / MS. Key plasma pharmacokinetic parameters were analyzed using data analysis software.
[0359] Table 2 Results of Rat Pharmacokinetic Test
[0360] The results of the pharmacokinetic studies in rats showed that the compound of the present invention exhibited excellent pharmacokinetic properties in rats and good drug-likeness.
[0361] Experimental Example 3: Test of the off-target inhibitory activity of the compound on acetylcholinesterase
[0362] The inhibitory activity of the compounds against acetylcholinesterase was tested using the Elman assay. The compounds were serially diluted with DMSO in a compound dilution plate. Different concentrations of the compounds were transferred to 384-well microplates using an Echo assay. Then, 10 μL of ACHE (Acro, AHE-H52H3) enzyme solution was added to each well of the 384-well microplate, with a final ACHE concentration of 0.015 nM. After centrifugation at 1000 rpm for 1 minute, the plates were incubated at 25°C for 15 minutes. Next, 10 μL of a mixed solution of ATC and DTNB (Sigma; A5626-1G & DTNB; D8130-1G) was added to each well of the microplate, with final ATC and DTNB concentrations of 300 μM and 100 μM, respectively. After centrifugation at 1000 rpm for 1 minute, the plates were incubated at 25°C for 90 minutes. The absorbance was then read at 405 nm using a BMG microplate reader. The inhibition rate of different concentrations of the compounds was calculated based on the absorbance values, and the IC50 of inhibition for different compounds was calculated using data fitting software. 50 .
[0363] Table 3 Acetylcholinesterase inhibition IC50 50
[0364] Experimental results show that the compound of this invention has weak inhibition of acetylcholinesterase, low off-target risk, and even lower risk of adverse clinical reactions.
[0365] Experimental Example 4: Plasma Protein Binding Rate of Compounds
[0366] The plasma protein binding rate of the compound was determined using the balanced dialysis method (HTD 96b). A 0.5 mM stock solution of the compound was prepared with DMSO, and then diluted 25-fold with 0.05 M sodium phosphate buffer to a 20 μM working solution. In a blank 96-well plate, 380 μL of plasma was added to each well, followed by 20 μL of working solution per well, and mixed thoroughly. The final compound concentration was 1 μM, containing 0.2% DMSO per well. 100 μL of 0.05 M sodium phosphate buffer was added to the receiver side of each dialysis chamber, and 100 μL of plasma containing the compound was added to the feed side. After capping, the plate was incubated at 37°C with shaking for 6 hours. After incubation, 25 μL samples were taken from both the feed and receiver sides of the dialysis chamber, pretreated, and analyzed by LC-MS / MS to calculate the plasma protein binding rate and free fraction of the compound.
[0367] Table 4. Free fractions of the tested compounds in plasma
[0368] The plasma protein binding rate test results of the compound showed that the compound of the present invention had a higher free fraction and higher free drug exposure in different species, and had good drug-like properties.
[0369] Experimental Example 5: In vivo efficacy test for urinary tract infections
[0370] In vivo efficacy studies for urinary tract infections were conducted using female C57BL / 6J mice. Four days prior to infection, each group received an intraperitoneal injection of 150 mg / kg cyclophosphamide (CTX), and one day prior to infection, received an intraperitoneal injection of 100 mg / kg CTX (cyclophosphamide). Simultaneously, one day prior to infection, the CFT-073 strain (Escherichia coli, BNCC354053) was inoculated into liquid culture medium in a BSL-2 laboratory and incubated at 37°C for 18 h using a bacterial turbidimeter. The bacterial concentration was calculated, and the bacterial solution was adjusted to an appropriate concentration using sterile PBS. Then, 50 μL of the bacterial solution was inoculated into the mouse bladder, with an inoculation volume of 1 × 10⁻⁶. 8 CFU. Two hours after inoculation, mice were administered a specific dose of the compound four times over 48 hours. After administration, mice were euthanized, and bladder tissue and one kidney were aseptically removed in a biosafety cabinet. The tissues were weighed, placed in sterile sample tubes, and homogenized with 0.5 mL of 0.5% Triton-PBS. The bacterial load was then plated. One-way ANOVA was performed using data processing software to assess the differences between each administered group and the model control group.
[0371] The in vivo efficacy test results for urinary tract infections showed that the compound of this invention exhibited good efficacy, significantly reduced the bacterial load in the bladder and kidneys of model animals, and had good drug-like properties.
Claims
1. The compound represented by formula (Ⅰ), its tautomers, stereoisomers, or pharmaceutically acceptable salts, in, W1, W2, W3, and W4 are each independently CR w Or N; Each R w The independent components are H, halogen, OH, NH2, CN, CONH2, and C, respectively. 1-6 Alkyl, C 1-6 Alkoxy or C 3-8 cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkoxy and C 3-8 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. ww replace; Each R ww They are H, halogen, OH, and C, respectively. 1-6 Alkyl or C 1-6 Alkoxy; Each R1 is independently H, oxo (=O), halogen, OH, NH2, CN, COOH, CONH2, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-8 cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkoxy and C 3-8 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. a replace; Each R a They are H, halogen, OH, and C, respectively. 1-6 Alkyl or C 1-6 Alkoxy; R2 represents H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups; X1, X2, X3, and X4 are each independently N or CR. x1 ; Each R x1 They are, independently, H, halogen, OH, NH2, CN, and C. 1-6 Alkyl, C 1-6 Alkylthio, C 1-6 Alkoxy, C 1-6 alkyl carbonyl, C 1-6 alkoxycarbonyl or C 3-8 cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkylthio, C 1-6 Alkoxy, C 1-6 alkyl carbonyl, C 1-6 alkoxycarbonyl and C 3-8 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. b replace; Each R b They are H, halogen, OH, NH2, and C, respectively. 1-6 Alkyl or C 1-6 Alkoxy; Ring A is C 3-10 Monocyclic cycloalkyl, C 4-10 Bicyclic cycloalkyl, 4-10 member monocyclic heterocyclic alkyl, 5-10 member bicyclic heterocyclic alkyl, 4-10 member monocyclic heterocyclic alkenyl or 5-10 member bicyclic heterocyclic alkenyl; Each R3 is independently H, oxo (=O), halogen, OH, NH2, CN, or C. 1-6 Alkyl, C 1-6 Alkoxy or C 3-8 cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkoxy and C 3-8 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. c replace; Each R c They are H, halogen, OH, NH2, and C, respectively. 1-6 Alkyl or C 1-6 Alkoxy; m can be 1, 2, 3, or 4; n is 1, 2, 3 or 4; The heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" contains N, O or S, and the number of the heteroatom groups is 1, 2, 3 or 4; when the number of the heteroatom groups is multiple, the heteroatom groups may be the same or different; The conditions are: When W1 and W4 are CR w When ring A is C 4-10 Bicyclic cycloalkyl, 5-10 membered bicyclic heterocyclic alkyl or 5-10 membered bicyclic heterocyclic alkenyl.
2. The compound according to claim 1, characterized in that, The compound satisfies one or more of the following conditions: 1a) Each R w The independent components are H, halogen, OH, NH2, CN, CONH2, and C, respectively. 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 cycloalkyl, the C 1-4 Alkyl, C 1-4 Alkoxy and C 3-6 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. ww replace; 2a) Each R w Each is independently represented by H; 3a) W1, W2, W3 and W4 are independently CH or N; 4a) W1, W2, and W3 are each independently CH, and W4 is N; 5a) W1, W2 and W4 are independently CH, and W3 is N; 6a) for 7a) for 8a) for 3. The compound according to claim 1, characterized in that, The compound satisfies one or more of the following conditions: 1b) Each R1 is independently H, halogen, OH, NH2, CN, COOH, CONH2, C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 cycloalkyl, the C 1-4 Alkyl, C 1-4 Alkoxy and C 3-6 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. a replace; 2b) Each R1 is independently H; 3b)m can be 1, 2, 3, or 4; 4b) R2 is H, C 1-3 Alkyl or C 1-3 Halogenated alkyl groups; 5b) R2 is H.
4. The compound according to claim 1, characterized in that, The compound satisfies one or more of the following conditions: 1c) Each R x1 They are, independently, H, halogen, OH, NH2, CN, and C. 1-4 Alkyl, C 1-4 Alkylthio, C 1-4 Alkoxy, C 1-4 alkyl carbonyl, C 1-4 alkoxycarbonyl or C 3-6 cycloalkyl, the C 1-4 Alkyl, C 1-4 Alkylthio, C 1-4 Alkoxy, C 1-4 alkyl carbonyl, C 1-4 alkoxycarbonyl and C 3-6 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. b replace; 2c) Each R x1 Each is independently represented by H; 3c) X1, X2, X3 and X4 are each independently N or CH; 4c) for 5c) X1, X2, and X4 are each independently CH, and X3 is N; or, X2, X3, and X4 are each independently CH, and X1 is N; 6c) for 7c) for 8c) Ring A is a 5-6 member monocyclic heterocyclic alkyl, a 6-8 member bicyclic heterocyclic alkyl, a 5-6 member monocyclic heterocyclic alkenyl or a 6-8 member bicyclic heterocyclic alkenyl; 9c) for When ring A is a 5-6 member monocyclic heterocyclic alkyl, a 6-8 member bicyclic heterocyclic alkyl, a 5-6 member monocyclic heterocyclic alkenyl, or a 6-8 member bicyclic heterocyclic alkenyl; or, for In this case, ring A is a 6-8 membered bicyclic heterocyclic alkyl group or a 6-8 membered bicyclic heterocyclic alkenyl group; 10c) Ring A is a 6-8 membered bicyclic heterocyclic alkyl group or a 6-8 membered bicyclic heterocyclic alkenyl group, wherein the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl group or the 6-8 membered bicyclic heterocyclic alkenyl group are each independently a spirocyclic ring, a bridged ring, or a fused ring; 11c) for When ring A is a 5-6 member monocyclic heterocyclic alkyl, a 6-8 member bicyclic heterocyclic alkyl, a 5-6 member monocyclic heterocyclic alkenyl, or a 6-8 member bicyclic heterocyclic alkenyl, the bicyclic rings in the 6-8 member bicyclic heterocyclic alkyl or 6-8 member bicyclic heterocyclic alkenyl are each independently a spirocyclic, bridged, or fused ring, and the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" is O; or, for When ring A is a 6-8 membered bicyclic heterocyclic alkyl or a 6-8 membered bicyclic heterocyclic alkenyl, the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl or the 6-8 membered bicyclic heterocyclic alkenyl are each independently a spirocyclic ring, and the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" is N; 12c) for Ring A is a 6-8 membered bicyclic heterocyclic alkyl or a 6-8 membered bicyclic heterocyclic alkenyl group, wherein the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl or 6-8 membered bicyclic heterocyclic alkenyl group are each independently a spirocyclic, bridged, or fused ring, and the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" group is O; or for Ring A is a 5-6 membered monocyclic heterocyclic alkyl or a 5-6 membered monocyclic heterocyclic alkenyl, wherein the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" is O; 13c) for R4 represents H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups; 14c) for R4 represents H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups; 15c) Each R3 is independently H, oxo (=O), halogen, OH, NH2, CN, C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 cycloalkyl, the C 1-4 Alkyl, C 1-4 Alkoxy and C 3-6 The cycloalkyl group is optionally surrounded by 1, 2, 3 or 4 R's. c replace; 16c) Each R3 is independently H or oxo (=O); 17c) Each R4 is independently H; 18c)n is 1, 2, 3 or 4; 19c) for 20c) for 5. The compound according to claim 1, characterized in that, The compound has structural formula (Ⅰ-1) or structural formula (Ⅰ-1A): in, Ring A is C 4-10 Bicyclic cycloalkyl, 5-10 membered bicyclic heterocyclic alkyl or 5-10 membered bicyclic heterocyclic alkenyl; R w R1, R2, R3, X1, X2, X3, X4, m, and n are as defined in claim 1.
6. The compound according to claim 5, characterized in that, The compound satisfies one or more of the following conditions: 1d) Ring A is a 6-8 membered bicyclic heterocyclic alkyl group or a 6-8 membered bicyclic heterocyclic alkenyl group; 2d) Ring A is a 6-8 membered bicyclic heterocyclic alkyl group or a 6-8 membered bicyclic heterocyclic alkenyl group, wherein the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl group or the 6-8 membered bicyclic heterocyclic alkenyl group are each independently a spirocyclic ring, a bridged ring, or a fused ring; 3d) for 4d) for 5d) for Ring A is a 6-8 membered bicyclic heterocyclic alkyl or a 6-8 membered bicyclic heterocyclic alkenyl group, wherein the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl or 6-8 membered bicyclic heterocyclic alkenyl group are each independently a spirocyclic, bridged, or fused ring, and the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" group is O; or for Ring A is a 6-8 membered bicyclic heterocyclic alkyl or a 6-8 membered bicyclic heterocyclic alkenyl, wherein each of the bicyclic rings in the 6-8 membered bicyclic heterocyclic alkyl or the 6-8 membered bicyclic heterocyclic alkenyl is independently a spirocyclic ring, and the heteroatom group in the "heterocyclic alkyl" or "heterocyclic alkenyl" is N; 6d) for 8d) for 7. The compound according to claim 1, characterized in that, Selected from any of the following compounds or their tautomers, stereoisomers or pharmaceutically acceptable salts:
8. The compound according to claim 1, characterized in that, Selected from any of the following compounds or their tautomers, stereoisomers or pharmaceutically acceptable salts:
9. A pharmaceutical composition, characterized in that, It comprises the compound of any one of claims 1-8 or its tautomer, stereoisomer or pharmaceutically acceptable salt; and optionally a pharmaceutically acceptable carrier.
10. Use of the compound or its tautomer, stereoisomer or pharmaceutically acceptable salt according to any one of claims 1-8, or the pharmaceutical composition according to claim 9, in the preparation of a medicament for treating or preventing infections and diseases caused by bacteria in mammals.
11. Use of the compound or its tautomer, stereoisomer or pharmaceutically acceptable salt according to any one of claims 1-8, or the pharmaceutical composition according to claim 9, for the treatment or prevention of infections and diseases caused by bacteria in mammals.
12. The compound of any one of claims 1-8 or its tautomer, stereoisomer or pharmaceutically acceptable salt, or the pharmaceutical composition of claim 9, for the treatment or prevention of infections and diseases caused by bacteria in mammals.
13. A method for treating or preventing infections and diseases caused by bacteria in mammals, characterized in that, include: Administer to a subject a pharmaceutically acceptable dose of any of claims 1-8, or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 9.
14. The use according to any one of claims 10 to 12 or the method according to claim 13, characterized in that, The infections include those caused by Neisseria gonorrhoeae or uncomplicated urinary tract infections.
15. The use according to any one of claims 10 to 12 or the method according to claim 13, characterized in that, The infections include those caused by Escherichia coli or Staphylococcus aureus.
